{
    "id": 5520,
    "name": "head and neck squamous cell carcinoma",
    "source": "DOID",
    "definition": "A head and neck carcinoma that has_material_basis_in squamous cells that line the moist, mucosal surfaces inside the head and neck. [url:http\\://en.wikipedia.org/wiki/Head_and_neck_cancer#Squamous_cell_carcinoma, url:http\\://www.cancer.gov/cancertopics/factsheet/Sites-Types/head-and-neck, url:http\\://www.cancer.gov/dictionary?CdrID=597171]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:5520",
    "evidence": [
        {
            "id": 1394,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Buparlisib (BKM-120) reduced viability of head and neck squamous cell carcinoma (HNSSC) cells in culture and demonstrated anti-tumor activity in HNSSC xenograft models (PMID: 22116303).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 680,
                "therapyName": "Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1144,
                    "pubMedId": 22116303,
                    "title": "Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22116303"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1401,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Adavosertib (MK-1775) inhibited proliferation in various tumor cell lines, including head and neck squamous cell carcinoma cell lines, in culture (PMID: 23699655).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 822,
                "therapyName": "Adavosertib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 80,
                    "pubMedId": 23699655,
                    "title": "Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23699655"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1405,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PF-05212384 decreased viability of head and neck squamous carcinoma cells harboring a PIK3CA activating mutation in cell culture (PMID: 24823695).",
            "molecularProfile": {
                "id": 743,
                "profileName": "PIK3CA act mut"
            },
            "therapy": {
                "id": 1040,
                "therapyName": "Gedatolisib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1065,
                    "pubMedId": 24823695,
                    "title": "The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24823695"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1407,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, head and neck squamous cell carcinoma patient-derived xenograft models harboring a PIK3CA E545K mutation demonstrated increased sensitivity to Rigosertib (ON 01910.Na) (PMID: 23873848).",
            "molecularProfile": {
                "id": 2421,
                "profileName": "PIK3CA E545K"
            },
            "therapy": {
                "id": 1046,
                "therapyName": "Rigosertib Sodium",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1151,
                    "pubMedId": 23873848,
                    "title": "The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23873848"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1505,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the treatment of a head and neck squamous cell carcinoma cell line with mutant TP53 (C176F and A161S) with AZD7762, a pan Chk1/2 inhibitor, sensitizes the cells to Platinol (cisplatin) (PMID: 23839309).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 1755,
                "therapyName": "AZD7762 + Cisplatin",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1211,
                    "pubMedId": 23839309,
                    "title": "Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23839309"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2207,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY2109761 induced an epithelioid phenotype and inhibited migration of HNSCC cells expressing TGFBR2 R537P (PMID: 18339844).",
            "molecularProfile": {
                "id": 6281,
                "profileName": "TGFBR2 R537P"
            },
            "therapy": {
                "id": 2711,
                "therapyName": "LY2109761",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2767,
                    "pubMedId": 18339844,
                    "title": "Cancer-associated transforming growth factor beta type II receptor gene mutant causes activation of bone morphogenic protein-Smads and invasive phenotype.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18339844"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2476,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a meta-analysis, Glucophage (metformin) treatment decreased recurrence and metastasis and improved overall survival of head and neck squamous cell carcinoma patients (PMID: 25636350).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1031,
                "therapyName": "Metformin",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3152,
                    "pubMedId": 25636350,
                    "title": "Effects of metformin on head and neck cancer: a systematic review.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25636350"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2477,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rapamune (sirolimus) decreased tumor growth and increased survival of cell line xenograft models of head and neck squamous cell carcinoma (PMID: 21520111).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3153,
                    "pubMedId": 21520111,
                    "title": "Efficacy and comparative effectiveness of sirolimus as an anticancer drug.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21520111"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2481,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, treatment with Torisel (temsirolimus) resulted in disease stabilization in 57.6% (19/33) and tumor shrinkage in 39.4% (13/33) of patients with head and neck squamous cell carcinoma (PMID: 25527417).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 936,
                "therapyName": "Temsirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3159,
                    "pubMedId": 25527417,
                    "title": "TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25527417"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2653,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gedatolisib (PF-05212384) increased the the sensitivity of head and neck squamous cancer cells to radiation as indicated by decreased downstream signaling of the PI3K/mTOR pathway and reduced growth both in culture and in cell line xenograft models (PMID: 25724523).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1040,
                "therapyName": "Gedatolisib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3372,
                    "pubMedId": 25724523,
                    "title": "Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25724523"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2689,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LGK974 inhibited growth of head and neck squamous cell carcinoma cells harboring NOTCH1 C478F in culture and xenograft models (PMID: 24277854).",
            "molecularProfile": {
                "id": 10166,
                "profileName": "NOTCH1 C478F"
            },
            "therapy": {
                "id": 1937,
                "therapyName": "LGK974",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3402,
                    "pubMedId": 24277854,
                    "title": "Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24277854"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3249,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGJ398 inhibited cell growth and induced apoptosis in HNSCC cells over expressing Fgfr1 in culture and in xenograft models (PMID: 26015511).",
            "molecularProfile": {
                "id": 4208,
                "profileName": "FGFR1 over exp"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3696,
                    "pubMedId": 26015511,
                    "title": "FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26015511"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3254,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, sinonasal squamous cell carcinoma cells harboring EGFR S768_D770dup demonstrated resistance to Iressa (gefinitib) in culture (PMID: 25931286).",
            "molecularProfile": {
                "id": 13009,
                "profileName": "EGFR S768_D770dup"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3698,
                    "pubMedId": 25931286,
                    "title": "High-Frequency Targetable EGFR Mutations in Sinonasal Squamous Cell Carcinomas Arising from Inverted Sinonasal Papilloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25931286"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3255,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, sinonasal squamous cell carcinoma cells harboring EGFR N771_H773dup demonstrated resistance to Iressa (gefinitib) in culture (PMID: 25931286).",
            "molecularProfile": {
                "id": 13013,
                "profileName": "EGFR N771_H773dup"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3698,
                    "pubMedId": 25931286,
                    "title": "High-Frequency Targetable EGFR Mutations in Sinonasal Squamous Cell Carcinomas Arising from Inverted Sinonasal Papilloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25931286"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3256,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, sinonasal squamous cell carcinoma cells harboring EGFR N771_H773dup demonstrated resistance to Tarceva (erlotinib) in culture (PMID: 25931286).",
            "molecularProfile": {
                "id": 13013,
                "profileName": "EGFR N771_H773dup"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3698,
                    "pubMedId": 25931286,
                    "title": "High-Frequency Targetable EGFR Mutations in Sinonasal Squamous Cell Carcinomas Arising from Inverted Sinonasal Papilloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25931286"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3257,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, sinonasal squamous cell carcinoma cells harboring EGFR S768_D770dup demonstrated resistance to Tarceva (erlotinib) in culture (PMID: 25931286).",
            "molecularProfile": {
                "id": 13009,
                "profileName": "EGFR S768_D770dup"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3698,
                    "pubMedId": 25931286,
                    "title": "High-Frequency Targetable EGFR Mutations in Sinonasal Squamous Cell Carcinomas Arising from Inverted Sinonasal Papilloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25931286"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3258,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nerlynx (neratinib) inhibited EGFR signaling and reduced growth of sinonasal squamous cell carcinoma cells harboring EGFR S768_D770dup in culture (PMID: 25931286).",
            "molecularProfile": {
                "id": 13009,
                "profileName": "EGFR S768_D770dup"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3698,
                    "pubMedId": 25931286,
                    "title": "High-Frequency Targetable EGFR Mutations in Sinonasal Squamous Cell Carcinomas Arising from Inverted Sinonasal Papilloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25931286"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3259,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nerlynx (neratinib) inhibited growth of sinonasal squamous cell carcinoma cells harboring EGFR N771_H773dup in culture (PMID: 25931286).",
            "molecularProfile": {
                "id": 13013,
                "profileName": "EGFR N771_H773dup"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3698,
                    "pubMedId": 25931286,
                    "title": "High-Frequency Targetable EGFR Mutations in Sinonasal Squamous Cell Carcinomas Arising from Inverted Sinonasal Papilloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25931286"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3375,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zolinza (vorinostat) inhibited growth of a head and neck squamous cell carcinoma cell line harboring FBXW7 R505C in culture (PMID: 23274910).",
            "molecularProfile": {
                "id": 1040,
                "profileName": "FBXW7 R505C"
            },
            "therapy": {
                "id": 1077,
                "therapyName": "Vorinostat",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 570,
                    "pubMedId": 23274910,
                    "title": "Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23274910"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3376,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zolinza (vorinostat) inhibited growth of a head and neck squamous cell carcinoma cell line harboring stabilized Mcl1 expression in culture (PMID: 23274910).",
            "molecularProfile": {
                "id": 10008,
                "profileName": "MCL1 over exp"
            },
            "therapy": {
                "id": 1077,
                "therapyName": "Vorinostat",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 570,
                    "pubMedId": 23274910,
                    "title": "Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23274910"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3377,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of ABT-737 and Zolinza (vorinostat) synergized to decrease viability of Zolinza (vorinostat)-resistant Bcl2-over-expressing human head and neck squamous cell carcinoma cell lines in culture and to reduce tumor volume in xenografts (PMID: 23274910).",
            "molecularProfile": {
                "id": 1785,
                "profileName": "BCL2 over exp"
            },
            "therapy": {
                "id": 3132,
                "therapyName": "ABT-737 + Vorinostat",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 570,
                    "pubMedId": 23274910,
                    "title": "Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23274910"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3610,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Istodax (romidepsin) demonstrated limited efficacy, as a monotherapy, in 14 patients with head and neck squamous cell carcinoma (PMID: 22748449).",
            "molecularProfile": {
                "id": 11680,
                "profileName": "BRD4 - NUTM1"
            },
            "therapy": {
                "id": 1075,
                "therapyName": "Romidepsin",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 3882,
                    "pubMedId": 22748449,
                    "title": "Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22748449"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3814,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, Tarceva (erlotinib) treatment resulted in disease-free survival for more than 2 years in an oral cavity squamous cell carcinoma patient harboring MAPK1 E322K mutation (PMID: 26181029).",
            "molecularProfile": {
                "id": 6671,
                "profileName": "MAPK1 E322K"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4188,
                    "pubMedId": 26181029,
                    "title": "Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26181029"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3913,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Taselisib (GDC-0032) enhanced the effects of radiation induced apoptosis in HNSCC cell lines, cell line xenograft models, and a patient derived xenograft (PDX) model, all with PIK3CA mutations (PMID: 26589432).",
            "molecularProfile": {
                "id": 429,
                "profileName": "PIK3CA mutant"
            },
            "therapy": {
                "id": 3967,
                "therapyName": "Radiotherapy + Taselisib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4291,
                    "pubMedId": 26589432,
                    "title": "Taselisib (GDC-0032), a Potent \u03b2-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26589432"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3914,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Taselisib (GDC-0032) enhanced the effects of radiation induced apoptosis in HNSCC cell lines and cell line xenograft models with PIK3CA amplification (PMID: 26589432).",
            "molecularProfile": {
                "id": 1191,
                "profileName": "PIK3CA amp"
            },
            "therapy": {
                "id": 3967,
                "therapyName": "Radiotherapy + Taselisib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4291,
                    "pubMedId": 26589432,
                    "title": "Taselisib (GDC-0032), a Potent \u03b2-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26589432"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3915,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, head and neck squamous cell carcinoma cell lines and cell line xenograft models with PTEN alterations were resistant to the apoptotic effects of Taselisib (GDC-0032) (PMID: 26589432).",
            "molecularProfile": {
                "id": 1213,
                "profileName": "PTEN mutant"
            },
            "therapy": {
                "id": 1016,
                "therapyName": "Taselisib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4291,
                    "pubMedId": 26589432,
                    "title": "Taselisib (GDC-0032), a Potent \u03b2-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26589432"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4077,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rogaratinib (BAY 1163877) inhibited tumor growth in a head and neck squamous cell carcinoma xenograft model with FGFR3 overexpression (Cancer Res August 1, 2015 75:772).",
            "molecularProfile": {
                "id": 8807,
                "profileName": "FGFR3 over exp"
            },
            "therapy": {
                "id": 2030,
                "therapyName": "Rogaratinib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4393,
                    "pubMedId": null,
                    "title": "Abstract 772: Anti-tumor efficacy of the selective pan-FGFR Inhibitor BAY 1163877 in preclinical squamous cell carcinoma models of different origin",
                    "url": "http://cancerres.aacrjournals.org/content/75/15_Supplement/772.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4466,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with OXi4503 resulted in increased tumor cell necrosis and decreased tumor growth and extended median survival in cell line xenograft models of head and neck squamous cell carcinoma (PMID: 26751478).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3524,
                "therapyName": "OXi4503",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4568,
                    "pubMedId": 26751478,
                    "title": "Preclinical Activity of the Vascular Disrupting Agent OXi4503 against Head and Neck Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26751478"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4687,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rapamune (sirolimus) worked synergistically with Mekinist (trametinib) to inhibit proliferation of head and neck squamous carcinoma cell lines harboring HRAS Q61L in culture and to reduce tumor growth in cell line xenograft models (PMID: 26882569).",
            "molecularProfile": {
                "id": 3563,
                "profileName": "HRAS Q61L"
            },
            "therapy": {
                "id": 3596,
                "therapyName": "Sirolimus + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4668,
                    "pubMedId": 26882569,
                    "title": "A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26882569"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4688,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rapamune (sirolimus) worked synergistically with Mekinist (trametinib) to inhibit proliferation of head and neck squamous carcinoma cell lines harboring PIK3CA H1047R in culture and to reduce tumor growth in cell line xenograft models (PMID: 26882569).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 3596,
                "therapyName": "Sirolimus + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4668,
                    "pubMedId": 26882569,
                    "title": "A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26882569"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4689,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rapamune (sirolimus) worked synergistically with Mekinist (trametinib) to inhibit proliferation of head and neck squamous carcinoma cell lines overexpressing KRAS G12V in culture and to reduce tumor growth in cell line xenograft models (PMID: 26882569).",
            "molecularProfile": {
                "id": 1127,
                "profileName": "KRAS G12V"
            },
            "therapy": {
                "id": 3596,
                "therapyName": "Sirolimus + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4668,
                    "pubMedId": 26882569,
                    "title": "A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26882569"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4820,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, head and neck squamous cell carcinoma cells treated with OSU03012 (AR-12) in both culture and mouse models demonstrated reduced Akt levels, a marker for Pdpk1 activity, and tumor regression (PMID: 22491800).",
            "molecularProfile": {
                "id": 19233,
                "profileName": "PDPK1 positive"
            },
            "therapy": {
                "id": 2408,
                "therapyName": "OSU03012",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4749,
                    "pubMedId": 22491800,
                    "title": "Antitumor mechanisms of targeting the PDK1 pathway in head and neck cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22491800"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5298,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGB-324 inhibited proliferation and invasion of head and neck squamous cell carcinoma cell lines positive for Axl expression in culture (PMID: 25767293).",
            "molecularProfile": {
                "id": 20482,
                "profileName": "AXL positive"
            },
            "therapy": {
                "id": 2660,
                "therapyName": "BGB-324",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4998,
                    "pubMedId": 25767293,
                    "title": "AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25767293"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5299,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGB-324 did not inhibit proliferation or invasion of AXL-negative head and neck squamous cell carcinoma cell lines in culture (PMID: 25767293).",
            "molecularProfile": {
                "id": 20484,
                "profileName": "AXL negative"
            },
            "therapy": {
                "id": 2660,
                "therapyName": "BGB-324",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4998,
                    "pubMedId": 25767293,
                    "title": "AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25767293"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5300,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGB-324 and Erbitux (cetuximab) worked synergistically to inhibit proliferation of Axl-positive head and neck squamous cell carcinoma cell lines in culture (PMID: 25767293).",
            "molecularProfile": {
                "id": 20482,
                "profileName": "AXL positive"
            },
            "therapy": {
                "id": 3825,
                "therapyName": "BGB-324 + Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4998,
                    "pubMedId": 25767293,
                    "title": "AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25767293"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5545,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pan-HER inhibited proliferation of cetuximab-sensitive and cetuximab-resistant head and neck squamous cell carcinoma cell lines demonstrating high basal protein level of Egfr, Erbb2 (Her2) and Erbb3 (Her3) in culture (PMID: 26420857).",
            "molecularProfile": {
                "id": 20975,
                "profileName": "EGFR over exp ERBB2 over exp ERBB3 over exp"
            },
            "therapy": {
                "id": 3885,
                "therapyName": "Pan-HER",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5091,
                    "pubMedId": 26420857,
                    "title": "Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26420857"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8158,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pan-HER inhibited HER family receptors expression and signaling, suppressed growth of acquired and intrinsically cetuximab-resistant head and neck squamous cell carcinoma cell lines demonstrating high protein level of Egfr, Erbb2 (Her2) and Erbb3 (Her3) in culture and in cell line xenograft models (PMID: 27422810).",
            "molecularProfile": {
                "id": 20975,
                "profileName": "EGFR over exp ERBB2 over exp ERBB3 over exp"
            },
            "therapy": {
                "id": 3885,
                "therapyName": "Pan-HER",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6563,
                    "pubMedId": 27422810,
                    "title": "Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27422810"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5549,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pan-HER sensitized both cetuximab-sensitive and cetuximab-resistant head and neck squamous cell carcinoma cell lines demonstrating high basal protein level of Egfr, Erbb2 (Her2) and Erbb3 (Her3) to radiation toxicity in culture and inhibited tumor growth in cell line xenograft models (PMID: 26420857).",
            "molecularProfile": {
                "id": 20975,
                "profileName": "EGFR over exp ERBB2 over exp ERBB3 over exp"
            },
            "therapy": {
                "id": 3886,
                "therapyName": "Pan-HER + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5091,
                    "pubMedId": 26420857,
                    "title": "Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26420857"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5866,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Taselisib (GDC-0032) enhanced the effects of radiation induced apoptosis of head and neck squamous carcinoma cells harboring PIK3CA H1047R (PMID: 26589432).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 3967,
                "therapyName": "Radiotherapy + Taselisib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4291,
                    "pubMedId": 26589432,
                    "title": "Taselisib (GDC-0032), a Potent \u03b2-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26589432"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5867,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, head and neck squamous cell carcinoma cells homozygous for PTEN deletion were resistant to Taselisib (GDC-0032) in culture (PMID: 26589432).",
            "molecularProfile": {
                "id": 2408,
                "profileName": "PTEN del"
            },
            "therapy": {
                "id": 1016,
                "therapyName": "Taselisib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4291,
                    "pubMedId": 26589432,
                    "title": "Taselisib (GDC-0032), a Potent \u03b2-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26589432"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6072,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) inhibited growth of head and neck squamous cell carcinoma (HNSCC) cell lines in culture, and inhibited tumor growth in HNSCC cell line xenograft models, with highest efficacy against EGFR-amplified cell lines (PMID: 25559287).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2348,
                    "pubMedId": 25559287,
                    "title": "Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25559287"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6073,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Erbitux (cetuximab) inhibited tumor growth in xenograft models of a head and neck squamous cell carcinoma cell line (PMID: 25559287).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 2348,
                    "pubMedId": 25559287,
                    "title": "Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25559287"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10850,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, head and neck squamous cell carcinoma cell lines, either human papilloma virus positive or negative, demonstrated decreased cell proliferation in culture when treated with Erlotinib (cetuximab) (PMID: 28138028).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8870,
                    "pubMedId": 28138028,
                    "title": "Combining Chk1/2 Inhibition with Cetuximab and Radiation Enhances In Vitro and In Vivo Cytotoxicity in Head and Neck Squamous Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28138028"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7130,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III clinical trial (BONNER) that supported FDA approval, treatment with Erbitux (cetuximab) in combination with radiotherapy resulted in a median survival of 49.0 months, compared to 29.3 months with radiotherapy alone, in patients with head and neck squamous cell carinoma (PMID: 16808060; NCT00004227).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6095,
                    "pubMedId": 16808060,
                    "title": "Cetuximab approved by FDA for treatment of head and neck squamous cell cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16808060"
                },
                {
                    "id": 15479,
                    "pubMedId": null,
                    "title": "Erbitux (cetuximab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125084"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6085,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Apitolisib (GDC-0980) treatment resulted in a partial response in a patient with head and neck squamous cell carcinoma harboring a PIK3CA E542K mutation (PMID: 26787751).",
            "molecularProfile": {
                "id": 808,
                "profileName": "PIK3CA E542K"
            },
            "therapy": {
                "id": 750,
                "therapyName": "GDC-0980",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4915,
                    "pubMedId": 26787751,
                    "title": "Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26787751"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6454,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CDX-3379 (KTN3379) inhibited tumor growth in xenograft models of head and neck squamous cell carcinoma expressing Erbb3 (Her3) and Nrg1 (Hrg) (PMID: 26880266).",
            "molecularProfile": {
                "id": 23514,
                "profileName": "ERBB3 pos NRG1 pos"
            },
            "therapy": {
                "id": 2054,
                "therapyName": "CDX-3379",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5601,
                    "pubMedId": 26880266,
                    "title": "A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26880266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6489,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Abemaciclib (LY2835219) reduced RB and AKT activation, and inhibited cell proliferation and colony formation in head and neck squamous cell carcinoma (HNSCC) cell lines in culture, and inhibited tumor growth in HNSCC xenograft models (PMID: 26909611).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 802,
                "therapyName": "Abemaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5661,
                    "pubMedId": 26909611,
                    "title": "The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26909611"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6490,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Abemaciclib (LY2835219) and Afinitor (everolimus) worked synergistically to reduce viability of head and neck squamous cell carcinoma (HNSCC) cells in culture, and to inhibit tumor growth in HNSCC cell line xenograft models, with increased efficacy over either agent alone (PMID: 26909611).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4127,
                "therapyName": "Abemaciclib + Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5661,
                    "pubMedId": 26909611,
                    "title": "The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26909611"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6491,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Abemaciclib (LY2835219) and Torin2 worked synergistically to reduce viability of head and neck squamous cell carcinoma cells in culture (PMID: 26909611).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4128,
                "therapyName": "Abemaciclib + Torin 2",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5661,
                    "pubMedId": 26909611,
                    "title": "The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26909611"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6933,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ABT-414 demonstrated cytoxicity against an EGFR-amplified head and neck squamous cell carcinoma (HNSCC) cell line in culture and induced tumor regression in EGFR-amplified HNSCC cell line xenograft models (PMID: 26846818).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 976,
                "therapyName": "Depatuxizumab mafodotin",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5960,
                    "pubMedId": 26846818,
                    "title": "ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26846818"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7131,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III clinical trial that supported FDA approval, Erbitux (cetuximab) in combination with platinum-based chemotherapy (Platinol (cisplatin) or Paraplatin (carboplatin)) and Adrucil (fluorouracil) resulted in a median overall survival of 10.1 months, versus 7.4 months with chemotherapy alone, in patients with recurrent or metastatic head and neck squamous cell carcinoma (PMID: 23576486).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1914,
                "therapyName": "Carboplatin + Cetuximab + Fluorouracil",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6099,
                    "pubMedId": 23576486,
                    "title": "Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23576486"
                },
                {
                    "id": 15479,
                    "pubMedId": null,
                    "title": "Erbitux (cetuximab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125084"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7192,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, MEHD7945A treatment resulted in partial response in 2 head and neck squamous cell carcinoma patients with high Hrg levels in tumor tissues (PMID: 26034219).",
            "molecularProfile": {
                "id": 24702,
                "profileName": "HRG over exp"
            },
            "therapy": {
                "id": 806,
                "therapyName": "Duligotuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6180,
                    "pubMedId": 26034219,
                    "title": "Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26034219"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7219,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient-derived FANCC-deficient head and neck squamous cell carcinoma cells demonstrated sensitivity to Lynparza (olaparib) in cell culture (PMID: 25609062).",
            "molecularProfile": {
                "id": 24787,
                "profileName": "FANCC loss"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6219,
                    "pubMedId": 25609062,
                    "title": "Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Sensitivity in Fanconi Anemia Head and Neck Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25609062"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7220,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient-derived FANCC-deficient head and neck squamous cell carcinoma cells demonstrated sensitivity to PJ-34 in cell culture (PMID: 25609062).",
            "molecularProfile": {
                "id": 24787,
                "profileName": "FANCC loss"
            },
            "therapy": {
                "id": 2541,
                "therapyName": "PJ34",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6219,
                    "pubMedId": 25609062,
                    "title": "Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Sensitivity in Fanconi Anemia Head and Neck Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25609062"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7712,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial (KEYNOTE-012) that supported FDA approval, treatment with Keytruda (pembrolizumab) resulted in an objective response rate of 18% (24/132; 4 complete response, 20 partial response) in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (PMID: 27247226; NCT01848834).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6455,
                    "pubMedId": null,
                    "title": "Preliminary results from KEYNOTE-055: Pembrolizumab after platinum and cetuximab failure in head and neck squamous cell carcinoma (HNSCC).",
                    "url": "http://meetinglibrary.asco.org/content/166094-176"
                },
                {
                    "id": 14053,
                    "pubMedId": 27247226,
                    "title": "Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27247226"
                },
                {
                    "id": 15508,
                    "pubMedId": null,
                    "title": "Keytruda (pembrolizumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7828,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD4547 treatment of head and neck squamous cell carcinoma cells over expressing FGFR1 and negative for EGFR resulted in decreased cell growth and reduced downstream signaling of Erk1/2 (PMID: 26936917).",
            "molecularProfile": {
                "id": 26061,
                "profileName": "EGFR neg FGFR1 over exp"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6507,
                    "pubMedId": 26936917,
                    "title": "FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26936917"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7830,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, head and neck squamous cell carcinoma cells with EGFR over expression and FGFR1 amplification demonstrated resistance to treatment with AZD4547 in culture (PMID: 26936917).",
            "molecularProfile": {
                "id": 26058,
                "profileName": "EGFR over exp FGFR1 amp"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6507,
                    "pubMedId": 26936917,
                    "title": "FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26936917"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7832,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, head and neck squamous cell carcinoma cells harboring FGFR2 amplification and over expressing EGFR demonstrated resistance to treatment with AZD4547 in culture (PMID: 26936917).",
            "molecularProfile": {
                "id": 26059,
                "profileName": "EGFR over exp FGFR2 amp"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6507,
                    "pubMedId": 26936917,
                    "title": "FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26936917"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7833,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, head and neck squamous cell carcinoma cells harboring FGFR1 amplification and over expressing EGFR demonstrated sensitivity to the combination treatment of AZD4547 and Iressa (gefitinib) in culture, which also resulted in a synergistic effect (PMID: 26936917).",
            "molecularProfile": {
                "id": 26058,
                "profileName": "EGFR over exp FGFR1 amp"
            },
            "therapy": {
                "id": 4585,
                "therapyName": "AZD4547 + Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6507,
                    "pubMedId": 26936917,
                    "title": "FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26936917"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7835,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, head and neck squamous cell carcinoma cells harboring FGFR2 amplification and over expressing EGFR demonstrated sensitivity to the combination treatment of AZD4547 and Iressa (gefitinib) in culture, which also resulted in a moderate synergistic effect (PMID: 26936917).",
            "molecularProfile": {
                "id": 26059,
                "profileName": "EGFR over exp FGFR2 amp"
            },
            "therapy": {
                "id": 4585,
                "therapyName": "AZD4547 + Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6507,
                    "pubMedId": 26936917,
                    "title": "FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26936917"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7885,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, head and neck squamous cell carcinoma cells harboring ERBB4 (HER4) G1109C were insensitive to treatment with Tarceva (erlotinib) in culture (PMID: 27207775).",
            "molecularProfile": {
                "id": 26082,
                "profileName": "ERBB4 G1109C"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6519,
                    "pubMedId": 27207775,
                    "title": "Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27207775"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7886,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, head and neck squamous cell carcinoma cells harboring ERBB4 (HER4) G1109C were insensitive to treatment with Erbitux (cetuximab) in culture (PMID: 27207775).",
            "molecularProfile": {
                "id": 26082,
                "profileName": "ERBB4 G1109C"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6519,
                    "pubMedId": 27207775,
                    "title": "Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27207775"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7888,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) treatment induced apoptosis in head and neck squamous cell carcinoma cells harboring ERBB4 (HER4) G1109C in culture and inhibited tumor growth in cell line xenograft models (PMID: 27207775).",
            "molecularProfile": {
                "id": 26082,
                "profileName": "ERBB4 G1109C"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6519,
                    "pubMedId": 27207775,
                    "title": "Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27207775"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7897,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, head and neck squamous cell carcinoma cells harboring EGFR amplification demonstrated resistance to Erbitux (cetuximab) in a cell viability assay (PMID: 27207775).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6519,
                    "pubMedId": 27207775,
                    "title": "Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27207775"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7898,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, head and neck squamous cell carcinoma cells harboring EGFR amplification demonstrated resistance to Tarceva (erlotinib) in a cell viability assay (PMID: 27207775).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6519,
                    "pubMedId": 27207775,
                    "title": "Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27207775"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8151,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Erbitux (cetuximab) and Revlimid (lenalidomide) combination therapy resulted in stable disease in 67% (2/3) of KRAS wild-type head and neck squamous cell cancer patients, and induced Revlimid (lenalidomide) dose-dependent increase of antibody-dependent cellular cytotoxicity (PMID: 27458141).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 4647,
                "therapyName": "Cetuximab + Lenalidomide",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6559,
                    "pubMedId": 27458141,
                    "title": "A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27458141"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8159,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pan-HER reduced Egfr, Erbb2 (Her2), and Erbb3 (Her3) protein levels and inhibited tumor growth in a xenograft model established from an Erbitux (cetuximab)-resistant head and neck squamous cell carcinoma patient (PMID: 27422810).",
            "molecularProfile": {
                "id": 26182,
                "profileName": "EGFR pos ERBB2 pos ERBB3 pos"
            },
            "therapy": {
                "id": 3885,
                "therapyName": "Pan-HER",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6563,
                    "pubMedId": 27422810,
                    "title": "Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27422810"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8241,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, some head and neck squamous cell carcinoma cell lines over expressing PIK3CA demonstrated sensitivity to treatment with Gedatolisib (PF-05212384) (PMID: 25977343).",
            "molecularProfile": {
                "id": 20299,
                "profileName": "PIK3CA over exp"
            },
            "therapy": {
                "id": 1040,
                "therapyName": "Gedatolisib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6585,
                    "pubMedId": 25977343,
                    "title": "MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25977343"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8244,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, head and neck squamous cell carcinoma cell lines harboring PIK3CA H1047R demonstrated sensitivity to treatment with Gedatolisib (PF-05212384) in culture (PMID: 25977343).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 1040,
                "therapyName": "Gedatolisib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6585,
                    "pubMedId": 25977343,
                    "title": "MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25977343"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8299,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a head and neck squamous cell carcinoma cell line with EGFR expression and over expression of ERBB3 (HER3) demonstrated sensitivity to treatment with MEHD7945A in culture, resulting in decreased cell proliferation (PMID: 26141946).",
            "molecularProfile": {
                "id": 26225,
                "profileName": "EGFR pos ERBB3 over exp"
            },
            "therapy": {
                "id": 806,
                "therapyName": "Duligotuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6593,
                    "pubMedId": 26141946,
                    "title": "Antitumor Effects of MEHD7945A, a Dual-Specific Antibody against EGFR and HER3, in Combination with Radiation in Lung and Head and Neck Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26141946"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8300,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, head and neck squamous cell carcinoma cell lines expressing EGFR and over expressing ERBB3 (HER3) demonstrated a decreased response to Erbitux (cetuximab) in culture when compared to MEHD7945A treatment (PMID: 26141946).",
            "molecularProfile": {
                "id": 26225,
                "profileName": "EGFR pos ERBB3 over exp"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6593,
                    "pubMedId": 26141946,
                    "title": "Antitumor Effects of MEHD7945A, a Dual-Specific Antibody against EGFR and HER3, in Combination with Radiation in Lung and Head and Neck Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26141946"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8301,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, head and neck squamous cell carcinoma cell lines expressing EGFR and over expressing ERBB3 (HER3) demonstrated a decreased response to treatment with a ERBB3 (HER3) antibody in culture when compared to MEHD7945A treatment (PMID: 26141946).",
            "molecularProfile": {
                "id": 26225,
                "profileName": "EGFR pos ERBB3 over exp"
            },
            "therapy": {
                "id": 4576,
                "therapyName": "unspecified ERBB3 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6593,
                    "pubMedId": 26141946,
                    "title": "Antitumor Effects of MEHD7945A, a Dual-Specific Antibody against EGFR and HER3, in Combination with Radiation in Lung and Head and Neck Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26141946"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8302,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, head and neck squamous cell carcinoma cells expressing EGFR and ERBB3 (HER3) were sensitive to treatment with MEHD7945A in culture, resulting in decreased cell proliferation (PMID: 26141946).",
            "molecularProfile": {
                "id": 26226,
                "profileName": "EGFR pos ERBB3 pos"
            },
            "therapy": {
                "id": 806,
                "therapyName": "Duligotuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6593,
                    "pubMedId": 26141946,
                    "title": "Antitumor Effects of MEHD7945A, a Dual-Specific Antibody against EGFR and HER3, in Combination with Radiation in Lung and Head and Neck Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26141946"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8305,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, radiation induced expression of EGFR and ERBB3 (HER3) in head and neck squamous cell carcinoma xenograft models demonstrated increased sensitivity when additionally treated with MEHD7945A, resulting in delayed tumor growth and increased DNA double stranded breaks (PMID: 26141946).",
            "molecularProfile": {
                "id": 26226,
                "profileName": "EGFR pos ERBB3 pos"
            },
            "therapy": {
                "id": 4683,
                "therapyName": "Duligotuzumab + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6593,
                    "pubMedId": 26141946,
                    "title": "Antitumor Effects of MEHD7945A, a Dual-Specific Antibody against EGFR and HER3, in Combination with Radiation in Lung and Head and Neck Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26141946"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8331,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CCT244747 inhibited Chek1 activation, resulted in sensitizing head and neck squamous cell carcinoma cell lines to radiation treatment in culture (PMID: 27422809).",
            "molecularProfile": {
                "id": 26229,
                "profileName": "CHEK1 positive"
            },
            "therapy": {
                "id": 4673,
                "therapyName": "CCT244747 + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6591,
                    "pubMedId": 27422809,
                    "title": "CHK1 Inhibition Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27422809"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8332,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CCT244747, Taxol (paclitaxel), and radiation triple therapy synergistically inhibited Chek1 activation, and resulted in growth inhibition of head and neck squamous cell carcinoma cell lines in culture and in cell line xenograft models (PMID: 27422809).",
            "molecularProfile": {
                "id": 26229,
                "profileName": "CHEK1 positive"
            },
            "therapy": {
                "id": 4674,
                "therapyName": "CCT244747 + Paclitaxel + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6591,
                    "pubMedId": 27422809,
                    "title": "CHK1 Inhibition Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27422809"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8832,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Debio 0617B inhibited survival of head and neck squamous cell carcinoma cell lines with activated Stat3 signaling in culture (PMID: 27439479).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 4822,
                "therapyName": "Debio 0617B",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6765,
                    "pubMedId": 27439479,
                    "title": "Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27439479"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9032,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGJ398 inhibited proliferation of a head and neck squamous cell carcinoma cell line expressing FGFR3 D788N in culture, however, cells expressing FGFR3 D788N did not demonstrate increased sensitivity to BGJ398 compared to cells expressing wild-type FGFR3 (PMID: 27053219).",
            "molecularProfile": {
                "id": 26694,
                "profileName": "FGFR3 D788N"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6884,
                    "pubMedId": 27053219,
                    "title": "Evaluation of FGFR3 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27053219"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9034,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a head and neck squamous cell carcinoma cell line expressing FGFR3 S131L demonstrated decreased sensitivity to BGJ398 compared to cells expressing wild-type FGFR3 in culture (PMID: 27053219).",
            "molecularProfile": {
                "id": 26695,
                "profileName": "FGFR3 S131L"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6884,
                    "pubMedId": 27053219,
                    "title": "Evaluation of FGFR3 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27053219"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9180,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Adavosertib (MK-1775) decreased MCL1 and XIAP expression level, inhibited growth of head and neck squamous cell carcinoma cell lines in culture and in cell line xenograft models (PMID: 26124202).",
            "molecularProfile": {
                "id": 26203,
                "profileName": "MCL1 positive"
            },
            "therapy": {
                "id": 822,
                "therapyName": "Adavosertib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6993,
                    "pubMedId": 26124202,
                    "title": "Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26124202"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9181,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Adavosertib (MK-1775) and Platinol (cisplatin) synergistically decreased MCL1 and XIAP expression level, inhibited growth of head and neck squamous cell carcinoma cell lines in culture and in cell line xenograft models (PMID: 26124202).",
            "molecularProfile": {
                "id": 26203,
                "profileName": "MCL1 positive"
            },
            "therapy": {
                "id": 1725,
                "therapyName": "Adavosertib + Cisplatin",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6993,
                    "pubMedId": 26124202,
                    "title": "Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26124202"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9206,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III clinical trial (CheckMate 141) that supported FDA approval, treatment with Opdivo (nivolumab) resulted in a 1 year overall survival rate of 36%, compared to 18% with standard therapy, and an improved median overall survival of 7.5 months, compared to 5.1 months with standard therapy, in patients with recurrent head and neck squamous cell carcinoma (PMID: 27718784; NCT02105636).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7020,
                    "pubMedId": 27718784,
                    "title": "Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27718784"
                },
                {
                    "id": 15569,
                    "pubMedId": null,
                    "title": "Opdivo (nivolumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9215,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, head and neck squamous cell carcinoma cells positive for BIRC2 and over expressing FADD demonstrated sensitivity to treatment with TL32711 (birinapant) with or without TNF-alpha, resulting in increased cell death and cell-cycle arrest in culture (PMID: 27469115).",
            "molecularProfile": {
                "id": 26783,
                "profileName": "BIRC2 pos FADD over exp"
            },
            "therapy": {
                "id": 2647,
                "therapyName": "Birinapant",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7034,
                    "pubMedId": 27469115,
                    "title": "SMAC Mimetic Birinapant plus Radiation Eradicates Human Head and Neck Cancers with Genomic Amplifications of Cell Death Genes FADD and BIRC2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27469115"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9216,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, head and neck squamous cell carcinoma cells harboring a CASP8 mutation and decreased expression of FADD demonstrated minimal sensitivity to TL32711 (birinapant), resulting in some cell death, but no cell-cycle arrest (PMID: 27469115).",
            "molecularProfile": {
                "id": 26784,
                "profileName": "CASP8 mut FADD dec exp"
            },
            "therapy": {
                "id": 2647,
                "therapyName": "Birinapant",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 7034,
                    "pubMedId": 27469115,
                    "title": "SMAC Mimetic Birinapant plus Radiation Eradicates Human Head and Neck Cancers with Genomic Amplifications of Cell Death Genes FADD and BIRC2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27469115"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9217,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a head and neck squamous cell carcinoma cell line positive for both BIRC2 and FADD demonstrated sensitivity to TL32711 (Birinapant), resulting in increased cell death in culture and decreased tumor volume in xenograft models (PMID: 27469115).",
            "molecularProfile": {
                "id": 26785,
                "profileName": "BIRC2 pos FADD pos"
            },
            "therapy": {
                "id": 2647,
                "therapyName": "Birinapant",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7034,
                    "pubMedId": 27469115,
                    "title": "SMAC Mimetic Birinapant plus Radiation Eradicates Human Head and Neck Cancers with Genomic Amplifications of Cell Death Genes FADD and BIRC2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27469115"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9218,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TL32711 (birinapant) combined with radiotherapy, which induced TNF-alpha, led to increased sensitivity in a head and neck squamous cell carcinoma cell line xenograft model positive for BIRC2 and over expressing FADD, demonstrating complete tumor regression (PMID: 27469115).",
            "molecularProfile": {
                "id": 26783,
                "profileName": "BIRC2 pos FADD over exp"
            },
            "therapy": {
                "id": 4953,
                "therapyName": "Birinapant + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7034,
                    "pubMedId": 27469115,
                    "title": "SMAC Mimetic Birinapant plus Radiation Eradicates Human Head and Neck Cancers with Genomic Amplifications of Cell Death Genes FADD and BIRC2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27469115"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9219,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TL32711 (Birinapant) combined with radiotherapy resulted in suppression of tumor growth in a head and neck squamous cell carcinoma cell line xenograft model over expressing FADD and BIRC2 (PMID: 27469115).",
            "molecularProfile": {
                "id": 26786,
                "profileName": "BIRC2 over exp FADD over exp"
            },
            "therapy": {
                "id": 4953,
                "therapyName": "Birinapant + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7034,
                    "pubMedId": 27469115,
                    "title": "SMAC Mimetic Birinapant plus Radiation Eradicates Human Head and Neck Cancers with Genomic Amplifications of Cell Death Genes FADD and BIRC2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27469115"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9220,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a head and neck squamous cell carcinoma cell line xenograft model with decreased expression of BIRC2 and FADD resulted in no benefit when treated with the combination of TL32711 (birinapant) and radiotherapy (PMID: 27469115).",
            "molecularProfile": {
                "id": 26788,
                "profileName": "BIRC2 dec exp FADD dec exp"
            },
            "therapy": {
                "id": 4953,
                "therapyName": "Birinapant + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7034,
                    "pubMedId": 27469115,
                    "title": "SMAC Mimetic Birinapant plus Radiation Eradicates Human Head and Neck Cancers with Genomic Amplifications of Cell Death Genes FADD and BIRC2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27469115"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9348,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD4547 and Vistusertib (AZD2014) synergistically inhibited survival of FGFR1-dependent head and neck squamous cell carcinoma cells in culture (PMID: 26359452).",
            "molecularProfile": {
                "id": 26138,
                "profileName": "FGFR1 positive"
            },
            "therapy": {
                "id": 4984,
                "therapyName": "AZD4547 + Vistusertib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7121,
                    "pubMedId": 26359452,
                    "title": "Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26359452"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9508,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of JPH203 (KYT-0353) and Glucophage (metformin) decreased proliferation of head and neck squamous cell cancer cell lines in culture, and reduced tumor growth in a head and neck squamous cell cancer cell line xenograft model (PMID: 27262901).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5049,
                "therapyName": "JPH203 + Metformin",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7238,
                    "pubMedId": 27262901,
                    "title": "Metformin enhances anti-tumor effect of L-type amino acid transporter 1 (LAT1) inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27262901"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9749,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a head and neck squamous cell carcinoma cell line expressing AXL demonstrated greater sensitivity to the combination of TP-0903 and Lynparza (olaparib) compared to either agent alone in culture, resulting in decreased colony formation, inhibition of cell growth, and increased apoptotic activity (PMID: 27671334).",
            "molecularProfile": {
                "id": 20482,
                "profileName": "AXL positive"
            },
            "therapy": {
                "id": 5188,
                "therapyName": "Olaparib + TP-0903",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7522,
                    "pubMedId": 27671334,
                    "title": "AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27671334"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10306,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NSC23766 decreased invasiveness of head and neck squamous cell carcinoma cell lines deficient in FANCD2 due to knockdown, in culture (PMID: 26603260).",
            "molecularProfile": {
                "id": 27345,
                "profileName": "FANCD2 negative"
            },
            "therapy": {
                "id": 5461,
                "therapyName": "NSC23766",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8297,
                    "pubMedId": 26603260,
                    "title": "Defects in the Fanconi Anemia Pathway in Head and Neck Cancer Cells Stimulate Tumor Cell Invasion through DNA-PK and Rac1 Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603260"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10700,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK1059615 treatment in a head and neck squamous cell carcinoma cell line resulted in inhibition of both cell growth and cell proliferation and induced necrosis in culture, and inhibited tumor growth in cell line xenograft models (PMID: 28187451).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2248,
                "therapyName": "GSK1059615",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8758,
                    "pubMedId": 28187451,
                    "title": "GSK1059615 kills head and neck squamous cell carcinoma cells possibly via activating mitochondrial programmed necrosis pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28187451"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12612,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Prexasertib (LY2606368) treatment resulted in partial response in a patient with head and neck squamous cell carcinoma (PMID: 27044938; NCT0115790).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1651,
                "therapyName": "Prexasertib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10479,
                    "pubMedId": 27044938,
                    "title": "Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27044938"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14570,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, treatment with Prexasertib (LY2606368) resulted in an overall response rate of 5% (3/57, all partial responses), clinical benefit rate (complete response+partial response+stable disease) of 49% (28/57), and a median progression-free survival of 1.6 months in patients with head and neck squamous cell carcinoma (PMID: 29643063; NCT0115790).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1651,
                "therapyName": "Prexasertib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11752,
                    "pubMedId": 29643063,
                    "title": "Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29643063"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10851,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, head and neck squamous cell carcinoma cell lines, either human papilloma virus positive or negative, demonstrated decreased cell proliferation in culture when treated with Prexasertib (LY2606368) (PMID: 28138028).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1651,
                "therapyName": "Prexasertib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8870,
                    "pubMedId": 28138028,
                    "title": "Combining Chk1/2 Inhibition with Cetuximab and Radiation Enhances In Vitro and In Vivo Cytotoxicity in Head and Neck Squamous Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28138028"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10852,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Erlotinib (cetuximab) and Prexasertib (LY2606368 resulted in greater decreased cell proliferation in head and neck squamous cell carcinoma cells in culture compared to either agent alone (PMID: 28138028).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1993,
                "therapyName": "Cetuximab + Prexasertib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8870,
                    "pubMedId": 28138028,
                    "title": "Combining Chk1/2 Inhibition with Cetuximab and Radiation Enhances In Vitro and In Vivo Cytotoxicity in Head and Neck Squamous Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28138028"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10853,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Prexasertib (LY2606368), Erlotinib (cetuximab), and radiotherapy resulted in greater decreased cell proliferation, inhibition of cell growth, and apoptotic activity in culture compared to either agent alone, and suppressed tumor growth in cell line xenograft models (PMID: 28138028).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5661,
                "therapyName": "Cetuximab + Prexasertib + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8870,
                    "pubMedId": 28138028,
                    "title": "Combining Chk1/2 Inhibition with Cetuximab and Radiation Enhances In Vitro and In Vivo Cytotoxicity in Head and Neck Squamous Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28138028"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10890,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Rigosertib (ON 01910.Na) treatment resulted in a partial response with 53% decrease of liver metastasis in a patients with head and neck squamous cell carcinoma harboring PTEN loss (Cancer Res April 15 2013 (73) (8 Supplement) LB-198).",
            "molecularProfile": {
                "id": 479,
                "profileName": "PTEN loss"
            },
            "therapy": {
                "id": 1046,
                "therapyName": "Rigosertib Sodium",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8903,
                    "pubMedId": null,
                    "title": "Abstract LB-198: Phase I and molecular correlates study of oral rigosertib in patients with refractory metastatic head and neck cancer and advanced solid tumors.",
                    "url": "http://cancerres.aacrjournals.org/content/73/8_Supplement/LB-198.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10912,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, Motolimod (VTX-2337) and Erbitux (cetuximab) combination treatment resulted in partial response in 15% (2/13) and stable disease in 39% (5/13) of patients with head and neck squamous cell carcinoma (PMID: 27810904).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5679,
                "therapyName": "Cetuximab + Motolimod",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8926,
                    "pubMedId": 27810904,
                    "title": "Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27810904"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11373,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, C188-9 inhibited Stat3 signaling, inhibited growth of head and neck squamous cell carcinoma cell lines in culture and in cell line xenograft models (PMID: 27027445).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 5961,
                "therapyName": "C188-9",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9260,
                    "pubMedId": 27027445,
                    "title": "Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27027445"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11508,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with AZD8055 resulted in antiproliferative activity in head and neck squamous cell carcinoma cells harboring PIK3CA amplification in culture (PMID: 28446642).",
            "molecularProfile": {
                "id": 1191,
                "profileName": "PIK3CA amp"
            },
            "therapy": {
                "id": 1519,
                "therapyName": "AZD8055",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9596,
                    "pubMedId": 28446642,
                    "title": "Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28446642"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11509,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with AZD8055 resulted in antiproliferative activity in head and neck squamous cell carcinoma cells harboring PTEN loss in culture (PMID: 28446642).",
            "molecularProfile": {
                "id": 479,
                "profileName": "PTEN loss"
            },
            "therapy": {
                "id": 1519,
                "therapyName": "AZD8055",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9596,
                    "pubMedId": 28446642,
                    "title": "Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28446642"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11510,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 resulted in antiproliferative activity in head and neck squamous cell carcinoma cells harboring PIK3CA amplification in culture (PMID: 28446642).",
            "molecularProfile": {
                "id": 1191,
                "profileName": "PIK3CA amp"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9596,
                    "pubMedId": 28446642,
                    "title": "Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28446642"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11511,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 resulted in antiproliferative activity in head and neck squamous cell carcinoma cells harboring PTEN loss in culture (PMID: 28446642).",
            "molecularProfile": {
                "id": 479,
                "profileName": "PTEN loss"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9596,
                    "pubMedId": 28446642,
                    "title": "Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28446642"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11512,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, two head and neck squamous cell carcinoma patient-derived xenograft (PDX) models harboring a PIK3CA activating mutation demonstrated greater delayed tumor growth when treated with a combination of AZD8055 and Erbitux (cetuximab) compared to either agent alone (PMID: 28446642).",
            "molecularProfile": {
                "id": 743,
                "profileName": "PIK3CA act mut"
            },
            "therapy": {
                "id": 6008,
                "therapyName": "AZD8055 + Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9596,
                    "pubMedId": 28446642,
                    "title": "Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28446642"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11851,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Sprycel (dasatinib) and Erbitux (cetuximab) combination treatment resulted in stable disease in 46% (6/13) and disease progression in 54% (7/13) of patients with cetuximab-resistant head and neck squamous cell carcinoma, with low serum IL6 level correlated with stable disease (PMID: 28559019).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1820,
                "therapyName": "Cetuximab + Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9869,
                    "pubMedId": 28559019,
                    "title": "IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28559019"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11935,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, head and neck squamous cell carcinoma cell lines with elevated expression of ERBB3 (HER3) and NRG1 were sensitive to treatment with Tykerb (lapatinib) in culture (PMID: 21840482).",
            "molecularProfile": {
                "id": 23514,
                "profileName": "ERBB3 pos NRG1 pos"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9923,
                    "pubMedId": 21840482,
                    "title": "Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21840482"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11953,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, addition of Erbitux (cetuximab) to induction chemotherapy consisting of Platinol (cisplatin), Taxotere (docetaxel), and Fluorouracil, resulted in early termination of the study due to unacceptable clinical outcomes (PMID: 28911062).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6212,
                "therapyName": "Cetuximab + Cisplatin + Docetaxel + Fluorouracil",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 9929,
                    "pubMedId": 28911062,
                    "title": "TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28911062"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11999,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including a partial remission in a patient with FGFR3-positive head and neck squamous cell carcinoma (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #379P; NCT01976741).",
            "molecularProfile": {
                "id": 9322,
                "profileName": "FGFR3 positive"
            },
            "therapy": {
                "id": 2030,
                "therapyName": "Rogaratinib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9963,
                    "pubMedId": null,
                    "title": "A novel mRNA-based patient selection strategy identifies fibroblast growth factor receptor (FGFR) inhibitor-sensitive tumors: Results from rogaratinib Phase-1 study",
                    "url": "http://www.esmo.org/Conferences/ESMO-2017-Congress/Abstracts"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12181,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, the combination of Torisel (temsirolimus), Paraplatin (carboplatin), and Taxol (paclitaxel) resulted in an objective response rate of 41.7% (15/36), which included all partial responses, and 52.3% (19/36) had stable disease (PMID: 28961834).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6333,
                "therapyName": "Carboplatin + Paclitaxel + Temsirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10139,
                    "pubMedId": 28961834,
                    "title": "A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28961834"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12182,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, a patient with head and neck squamous cell carcinoma harboring PIK3CA E545K demonstrated a partial response when treated with the combination of Torisel (temsirolimus), Paraplatin (carboplatin), and Taxol (paclitaxel) (PMID: 28961834).",
            "molecularProfile": {
                "id": 2421,
                "profileName": "PIK3CA E545K"
            },
            "therapy": {
                "id": 6333,
                "therapyName": "Carboplatin + Paclitaxel + Temsirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10139,
                    "pubMedId": 28961834,
                    "title": "A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28961834"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12183,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, two patients with head and neck squamous cell carcinoma harboring a PIK3CA mutation who had stable disease demonstrated some tumor regression when treated with the combination of Torisel (temsirolimus), Paraplatin (carboplatin), and Taxol (paclitaxel) (PMID: 28961834).",
            "molecularProfile": {
                "id": 429,
                "profileName": "PIK3CA mutant"
            },
            "therapy": {
                "id": 6333,
                "therapyName": "Carboplatin + Paclitaxel + Temsirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10139,
                    "pubMedId": 28961834,
                    "title": "A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28961834"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12184,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, a patient with head and neck squamous cell carcinoma harboring AKT3 W330C demonstrated a partial response when treated with the combination of Torisel (temsirolimus), Paraplatin (carboplatin), and Taxol (paclitaxel) (PMID: 28961834).",
            "molecularProfile": {
                "id": 28513,
                "profileName": "AKT3 W330C"
            },
            "therapy": {
                "id": 6333,
                "therapyName": "Carboplatin + Paclitaxel + Temsirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10139,
                    "pubMedId": 28961834,
                    "title": "A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28961834"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12185,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, a patient with head and neck squamous cell carcinoma harboring PTEN R130Q demonstrated a partial response when treated with the combination of Torisel (temsirolimus), Paraplatin (carboplatin), and Taxol (paclitaxel) (PMID: 28961834).",
            "molecularProfile": {
                "id": 4174,
                "profileName": "PTEN R130Q"
            },
            "therapy": {
                "id": 6333,
                "therapyName": "Carboplatin + Paclitaxel + Temsirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10139,
                    "pubMedId": 28961834,
                    "title": "A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28961834"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12438,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, decreased Smad4 expression level correlated with Erbitux (cetuximab) resistance in head and neck squamous cell carcinoma (HNSCC) patients, which is consistent with cell culture studies demonstrating Erbitux (cetuximab) resistance induced by knocking-down of Smad4 expression in HNSCC cell lines (PMID: 28522603).",
            "molecularProfile": {
                "id": 16537,
                "profileName": "SMAD4 dec exp"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10371,
                    "pubMedId": 28522603,
                    "title": "SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28522603"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12446,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SP600125 demonstrated modest inhibition of Jnk activity and transient growth inhibition in Smad4 knocked-down head and neck squamous cell carcinoma cells in culture (PMID: 28522603).",
            "molecularProfile": {
                "id": 16537,
                "profileName": "SMAD4 dec exp"
            },
            "therapy": {
                "id": 3366,
                "therapyName": "SP600125",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 10371,
                    "pubMedId": 28522603,
                    "title": "SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28522603"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12452,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, U0126 demonstrated modest inhibition of Mapk activity and transient growth inhibition in Smad4 knocked-down head and neck squamous cell carcinoma cells in culture (PMID: 28522603).",
            "molecularProfile": {
                "id": 16537,
                "profileName": "SMAD4 dec exp"
            },
            "therapy": {
                "id": 2427,
                "therapyName": "U0126",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 10371,
                    "pubMedId": 28522603,
                    "title": "SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28522603"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12458,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, addition of U0126 to Erbitux (cetuximab) restored sensitivity to Erbitux (cetuximab) in Smad4 knocked-down head and neck squamous cell carcinoma cells in culture (PMID: 28522603).",
            "molecularProfile": {
                "id": 16537,
                "profileName": "SMAD4 dec exp"
            },
            "therapy": {
                "id": 6489,
                "therapyName": "Cetuximab + U0126",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10371,
                    "pubMedId": 28522603,
                    "title": "SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28522603"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12461,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, addition of SP600125 to Erbitux (cetuximab) restored sensitivity to Erbitux (cetuximab) in Smad4 knocked-down head and neck squamous cell carcinoma cells in culture (PMID: 28522603).",
            "molecularProfile": {
                "id": 16537,
                "profileName": "SMAD4 dec exp"
            },
            "therapy": {
                "id": 6488,
                "therapyName": "Cetuximab + SP600125",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10371,
                    "pubMedId": 28522603,
                    "title": "SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28522603"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12670,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) inhibited cell migration and invasion of head and neck squamous cell carcinoma cells overexpressing Ddr2, in culture (PMID: 27434411).",
            "molecularProfile": {
                "id": 28831,
                "profileName": "DDR2 over exp"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10581,
                    "pubMedId": 27434411,
                    "title": "Targeting DDR2 in head and neck squamous cell carcinoma with dasatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27434411"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13143,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, treatment with Votrient (pazopanib) resulted in reduced tumor size in a patient with head and neck squamous cell carcinoma harboring FGFR2 P253R (PMID: 23786770).",
            "molecularProfile": {
                "id": 3429,
                "profileName": "FGFR2 P253R"
            },
            "therapy": {
                "id": 848,
                "therapyName": "Pazopanib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 2132,
                    "pubMedId": 23786770,
                    "title": "Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23786770"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14020,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (BERIL-1) trial, Buparlisib (BKM120) and Taxol (paclitaxel) combination treatment resulted in improved overall survival (HR=0.52) and prolonged progression-free survival (HR=0.45) in head and neck squamous cell carcinoma patients harboring TP53 mutations compared to TP53 wild-type patients (PMID: 29490986; NCT01852292).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 1545,
                "therapyName": "Buparlisib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11417,
                    "pubMedId": 29490986,
                    "title": "Molecular Alterations and Buparlisib Efficacy in Patients with Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis from BERIL-1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29490986"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 14021,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (BERIL-1) trial, Buparlisib (BKM120) and Taxol (paclitaxel) combination treatment resulted in improved overall survival in head and neck squamous cell carcinoma patients with low tumor mutational burden (HR=0.57) (PMID: 29490986; NCT01852292).",
            "molecularProfile": {
                "id": 29717,
                "profileName": "TMB low"
            },
            "therapy": {
                "id": 1545,
                "therapyName": "Buparlisib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11417,
                    "pubMedId": 29490986,
                    "title": "Molecular Alterations and Buparlisib Efficacy in Patients with Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis from BERIL-1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29490986"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 14120,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a head and neck squamous cell carcinoma patient-derived xenograft (PDX) model harboring ETV6-NTRK3 was sensitive to treatment with Merestinib (LY2801653) compared to vehicle, demonstrating decreased tumor growth (PMID: 29568395).",
            "molecularProfile": {
                "id": 2514,
                "profileName": "ETV6 - NTRK3"
            },
            "therapy": {
                "id": 1030,
                "therapyName": "Merestinib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11467,
                    "pubMedId": 29568395,
                    "title": "Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29568395"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14467,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, neoadjuvant treatment with Adavosertib (MK-1775) in combination with Platinol (cisplatin) and Taxotere (docetaxel) was well-tolerated and demonstrated preliminary anti-tumor activity in patients with head and neck squamous cell carcinoma, resulting in partial response in 5 patients and stable disease in 4 patients, out of 10 evaluable patients (PMID: 29535125).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 7092,
                "therapyName": "Adavosertib + Cisplatin + Docetaxel",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11637,
                    "pubMedId": 29535125,
                    "title": "A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29535125"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15034,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGJ398 inhibited proliferation of a head and neck squamous cell carcinoma cell line expressing FGFR3 D764H in culture, however, cells expressing FGFR3 D764H did not demonstrate increased sensitivity to BGJ398 compared to cells expressing wild-type FGFR3 (PMID: 27053219).",
            "molecularProfile": {
                "id": 30611,
                "profileName": "FGFR3 D764H"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6884,
                    "pubMedId": 27053219,
                    "title": "Evaluation of FGFR3 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27053219"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15200,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Verzenio (abemaciclib) treatment inhibited Rb1 phosphorylation and tumor growth in patient-derived xenograft (PDX) models of head and neck squamous cell carcinoma harboring CCND1 amplification and CDKN2A A68fs (PMID: 30380421).",
            "molecularProfile": {
                "id": 30826,
                "profileName": "CCND1 amp CDKN2A A68fs"
            },
            "therapy": {
                "id": 802,
                "therapyName": "Abemaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12822,
                    "pubMedId": 30380421,
                    "title": "Patient-Derived Xenografts for Prognostication and Personalized Treatment for Head and Neck Squamous Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30380421"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15201,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Verzenio (abemaciclib) treatment inhibited tumor growth in patient-derived xenograft (PDX) models of head and neck squamous cell carcinoma harboring CCND1 amplification and CDKN2A D84N (PMID: 30380421).",
            "molecularProfile": {
                "id": 30827,
                "profileName": "CCND1 amp CDKN2A D84N"
            },
            "therapy": {
                "id": 802,
                "therapyName": "Abemaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12822,
                    "pubMedId": 30380421,
                    "title": "Patient-Derived Xenografts for Prognostication and Personalized Treatment for Head and Neck Squamous Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30380421"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15202,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Verzenio (abemaciclib) treatment inhibited Rb1 phosphorylation and tumor growth in patient-derived xenograft (PDX) models of head and neck squamous cell carcinoma harboring CCND1 amplification and CDKN2A mutations (PMID: 30380421).",
            "molecularProfile": {
                "id": 30828,
                "profileName": "CCND1 amp CDKN2A mut"
            },
            "therapy": {
                "id": 802,
                "therapyName": "Abemaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12822,
                    "pubMedId": 30380421,
                    "title": "Patient-Derived Xenografts for Prognostication and Personalized Treatment for Head and Neck Squamous Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30380421"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15203,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Verzenio (abemaciclib) treatment inhibited tumor growth in patient-derived xenograft (PDX) models of head and neck squamous cell carcinoma harboring CCND1 amplification (PMID: 30380421).",
            "molecularProfile": {
                "id": 1420,
                "profileName": "CCND1 amp"
            },
            "therapy": {
                "id": 802,
                "therapyName": "Abemaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12822,
                    "pubMedId": 30380421,
                    "title": "Patient-Derived Xenografts for Prognostication and Personalized Treatment for Head and Neck Squamous Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30380421"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15204,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Verzenio (abemaciclib) treatment inhibited tumor growth in patient-derived xenograft (PDX) models of head and neck squamous cell carcinoma harboring wild-type CCND1 and CDKN2A R80* (PMID: 30380421).",
            "molecularProfile": {
                "id": 30829,
                "profileName": "CCND1 wild-type CDKN2A R80*"
            },
            "therapy": {
                "id": 802,
                "therapyName": "Abemaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12822,
                    "pubMedId": 30380421,
                    "title": "Patient-Derived Xenografts for Prognostication and Personalized Treatment for Head and Neck Squamous Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30380421"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15205,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Verzenio (abemaciclib) treatment did not inhibit tumor growth in patient-derived xenograft (PDX) models of head and neck squamous cell carcinoma harboring wild-type CCND1 and CDKN2A (PMID: 30380421).",
            "molecularProfile": {
                "id": 30830,
                "profileName": "CCND1 wild-type CDKN2A wild-type"
            },
            "therapy": {
                "id": 802,
                "therapyName": "Abemaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 12822,
                    "pubMedId": 30380421,
                    "title": "Patient-Derived Xenografts for Prognostication and Personalized Treatment for Head and Neck Squamous Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30380421"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15226,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cisplatin treatment of head and neck squamous cell carcinoma cells and cell line xenogratfs overexpressing Prom1 (Cd133) were resistant to cell-cycle inhibition as demonstrated by increased cell viability (PMID: 28381190).",
            "molecularProfile": {
                "id": 30836,
                "profileName": "PROM1 over exp"
            },
            "therapy": {
                "id": 700,
                "therapyName": "Cisplatin",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 12892,
                    "pubMedId": 28381190,
                    "title": "Ectopic overexpression of CD133 in HNSCC makes it resistant to commonly used chemotherapeutics.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28381190"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15227,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, fluorouracil (5-FU) treatment of head and neck squamous cell carcinoma cells and cell line xenogratfs overexpressing Prom1 (Cd133) were resistant to cell-cycle inhibition as demonstrated by increased cell viability (PMID: 28381190).",
            "molecularProfile": {
                "id": 30836,
                "profileName": "PROM1 over exp"
            },
            "therapy": {
                "id": 1715,
                "therapyName": "Fluorouracil",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 12892,
                    "pubMedId": 28381190,
                    "title": "Ectopic overexpression of CD133 in HNSCC makes it resistant to commonly used chemotherapeutics.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28381190"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15757,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib clinical trial, combined therapy, Votrient (pazopanib) and Erbitux (cetuximab), was well tolerated in head and neck squamous cell carcinoma patients with metastatic or resistant disease, and resulted in a 6% (2/31) complete response rate, a 29% (9/31) partial response rate, a median time to progression of 5.5 months, and a median overall survival of 9.5 months (PMID: 30001987; NCT01716416).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1838,
                "therapyName": "Cetuximab + Pazopanib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 13740,
                    "pubMedId": 30001987,
                    "title": "Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30001987"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15935,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib clinical trial, combined Erbitux (cetuximab), Patritumab (U3-1287), and Platinol (cisplatin) treatment was tolerable in patients with recurrent/metastatic head and neck squamous cell carcinoma and resulted in a 47% (7/15) overall response rate (3 complete responses and 4 partial responses), stable disease in 53% (8/15) of patients, a 7.9-month median progression-free survival, and a 13.5-month overall survival (PMID: 30327312; NCT02350712).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 7817,
                "therapyName": "Cetuximab + Cisplatin + Patritumab",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 14017,
                    "pubMedId": 30327312,
                    "title": "Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30327312"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15955,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, combined Erbitux (cetuximab) and Monalizumab (IPH2201) treatment was well tolerated in patients with recurrent or metastatic head and neck squamous cell carcinoma, and resulted in a 31% (8/26) objective response rate (partial responses) and stable disease in 54% (14/26) of evaluable patients (PMID: 30503213; NCT02643550).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3383,
                "therapyName": "Cetuximab + IPH2201",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 13989,
                    "pubMedId": 30503213,
                    "title": "Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30503213"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16233,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, combined Erbitux (cetuximab) and radiotherapy plus intratumoral delivery of EGFR antisense DNA was well tolerated by patients with head and neck squamous cell carcinoma and showed preliminary efficacy with complete responses in 66.7% (4/6) of patients and one partial response (PMID: 30291796; NCT00903461; NCT01592721).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 7971,
                "therapyName": "Cetuximab + EGFR Antisense DNA + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 14374,
                    "pubMedId": 30291796,
                    "title": "Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30291796"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16325,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination treatment with Erbitux (cetuximab) and intratumoral injection of EGFR antisense DNA reduced EGFR expression and tumor growth rate in a head and neck squamous cell carcinoma cell line xenograft mouse model to a greater extent than either treatment alone (PMID: 30291796).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8002,
                "therapyName": "Cetuximab + EGFR Antisense DNA",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 14374,
                    "pubMedId": 30291796,
                    "title": "Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30291796"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16660,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, combination of Erbitux (cetuximab) with Platinol (cisplatin) tended to improve progression-free survival compared to placebo in PTEN-expressing, PIK3CA wild-type head and neck squamous cell carcinoma patients (HR=0.54, p=0.0502) by multivariable analysis, but not in PTEN null or PIK3CA mutated patients (HR=0.76, p=0.54) (PMID: 30926065).",
            "molecularProfile": {
                "id": 31740,
                "profileName": "PIK3CA wild-type PTEN pos"
            },
            "therapy": {
                "id": 1915,
                "therapyName": "Cetuximab + Cisplatin",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14707,
                    "pubMedId": 30926065,
                    "title": "PTEN loss is associated with resistance to cetuximab in patients with head and neck squamous cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30926065"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16661,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, high PTEN expression was associated with improved progression-free survival (HR=0.35, p=0.008) in head and neck squamous cell carcinoma patients treated with Erbitux (cetuximab) with or without Nexavar (sorafenib) (PMID: 30926065).",
            "molecularProfile": {
                "id": 18161,
                "profileName": "PTEN positive"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14707,
                    "pubMedId": 30926065,
                    "title": "PTEN loss is associated with resistance to cetuximab in patients with head and neck squamous cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30926065"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16845,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, WSD0922 treatment resulted in tumor regression in patient-derived xenograft (PDX) models of cetuximab-resistant head and neck squamous cell carcinoma harboring EGFR activating mutations (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1326).",
            "molecularProfile": {
                "id": 423,
                "profileName": "EGFR act mut"
            },
            "therapy": {
                "id": 8206,
                "therapyName": "WSD0922",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14952,
                    "pubMedId": null,
                    "title": "WSD0922: A BBB penetrable EGFR/EGFRVIII inhibitor for the treatment of GBM and metastatic CNS tumor",
                    "url": "https://www.aacr.org/Documents/AACR_2019_Proceedings.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17350,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (KEYNOTE-048) that supported FDA approval, Keytruda (pembrolizumab) in combination with platinum and Adrucil (fluorouracil) significantly improved overall survival compared to Erbitux (cetuximab) plus chemotherapy (13.0 vs 10.7 months, HR=0.77, p=0.0067) in patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma (J Clin Oncol 37, no. 15_suppl (May 20 2019) 6000-6000; NCT02358031).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8464,
                "therapyName": "Carboplatin + Fluorouracil + Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 15386,
                    "pubMedId": null,
                    "title": "Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).",
                    "url": "https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.6000"
                },
                {
                    "id": 15508,
                    "pubMedId": null,
                    "title": "Keytruda (pembrolizumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17351,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (KEYNOTE-048) that supported FDA approval, Keytruda (pembrolizumab) in combination with platinum and Adrucil (fluorouracil) significantly improved overall survival compared to Erbitux (cetuximab) plus chemotherapy (13.0 vs 10.7 months, HR=0.77, p=0.0067) in patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma (J Clin Oncol 37, no. 15_suppl (May 20 2019) 6000-6000; NCT02358031).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6051,
                "therapyName": "Cisplatin + Fluorouracil + Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 15386,
                    "pubMedId": null,
                    "title": "Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).",
                    "url": "https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.6000"
                },
                {
                    "id": 15508,
                    "pubMedId": null,
                    "title": "Keytruda (pembrolizumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18807,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Keytruda (pembrolizumab) is included in guidelines as first-line therapy for patients with CD274 (PD-L1)-positive recurrent, unresectable, or metastatic non-nasopharyngeal head and neck squamous cell carcinoma (NCCN.org).",
            "molecularProfile": {
                "id": 4746,
                "profileName": "CD274 positive"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17352,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (KEYNOTE-048) that supported FDA approval, Keytruda (pembrolizumab) monotherapy significantly improved overall survival compared to Erbitux (cetuximab) plus chemotherapy (12.3 vs 10.3 months, HR=0.78, p=0.0171) in patients with CD274 (PD-L1)-positive (CPS equal to or greater than 1%) metastatic or unresectable recurrent head and neck squamous cell carcinoma (J Clin Oncol 37, no. 15_suppl (May 20 2019) 6000-6000; NCT02358031).",
            "molecularProfile": {
                "id": 4746,
                "profileName": "CD274 positive"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15386,
                    "pubMedId": null,
                    "title": "Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).",
                    "url": "https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.6000"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15508,
                    "pubMedId": null,
                    "title": "Keytruda (pembrolizumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18140,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, head and neck squamous cell carcinoma cells harboring PIK3CA H1047R treated with SHR-A1307 demonstrated inhibition of cell growth in culture (PMID: 30962319).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 8671,
                "therapyName": "SHR-A1307",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16007,
                    "pubMedId": 30962319,
                    "title": "Discovery of A Novel EGFR-Targeting Antibody-Drug Conjugate, SHR-A1307, for the Treatment of Solid Tumors Resistant or Refractory to Anti-EGFR Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30962319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18141,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, head and neck squamous cell carcinoma cells harboring PIK3CA H1047R were resistant to Erbitux (cetuximab) in culture (PMID: 30962319).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16007,
                    "pubMedId": 30962319,
                    "title": "Discovery of A Novel EGFR-Targeting Antibody-Drug Conjugate, SHR-A1307, for the Treatment of Solid Tumors Resistant or Refractory to Anti-EGFR Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30962319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18808,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Combination Keytruda (pembrolizumab), Paraplatin (carboplatin) and Adrucil (fluorouracil) is included in guidelines as a preferred first-line therapy for patients with CD274 (PD-L1)-positive recurrent, unresectable, or metastatic non-nasopharyngeal head and neck squamous cell carcinoma (NCCN.org).",
            "molecularProfile": {
                "id": 4746,
                "profileName": "CD274 positive"
            },
            "therapy": {
                "id": 8464,
                "therapyName": "Carboplatin + Fluorouracil + Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18809,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Combination Keytruda (pembrolizumab), Platinol (cisplatin) and Adrucil (fluorouracil) is included in guidelines as a preferred first-line therapy for patients with CD274 (PD-L1)-positive recurrent, unresectable, or metastatic non-nasopharyngeal head and neck squamous cell carcinoma (NCCN.org).",
            "molecularProfile": {
                "id": 4746,
                "profileName": "CD274 positive"
            },
            "therapy": {
                "id": 6051,
                "therapyName": "Cisplatin + Fluorouracil + Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19268,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Rigosertib (ON 01910.Na) treatment resulted in a complete response with disappearance of mediastinal and lung disease in a patients with head and neck squamous cell carcinoma harboring PIK3CA amplification (Cancer Res April 15 2013 (73) (8 Supplement) LB-198).",
            "molecularProfile": {
                "id": 1191,
                "profileName": "PIK3CA amp"
            },
            "therapy": {
                "id": 1046,
                "therapyName": "Rigosertib Sodium",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8903,
                    "pubMedId": null,
                    "title": "Abstract LB-198: Phase I and molecular correlates study of oral rigosertib in patients with refractory metastatic head and neck cancer and advanced solid tumors.",
                    "url": "http://cancerres.aacrjournals.org/content/73/8_Supplement/LB-198.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19399,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, CDX-3379 (KTN3379) treatment decreased tumor Erbb3 phosphorylation levels in 83% (10/12) of patients with head and neck squamous cell carcinoma, with 50% or more reduction in 58% (7/12) of patients, and 42% (5/12) patients achieved shrinkage of tumor burden (PMID: 31308059; NCT02473731).",
            "molecularProfile": {
                "id": 10756,
                "profileName": "ERBB3 positive"
            },
            "therapy": {
                "id": 2054,
                "therapyName": "CDX-3379",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16981,
                    "pubMedId": 31308059,
                    "title": "Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31308059"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19408,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a head and neck squamous cell carcinoma cell line harboring NOTCH1 C478F demonstrated apoptotic activity and reduced colony growth in culture and tumor regression in cell line xenograft models when treated with GSK2126458 (PMID: 30770351).",
            "molecularProfile": {
                "id": 10166,
                "profileName": "NOTCH1 C478F"
            },
            "therapy": {
                "id": 763,
                "therapyName": "GSK2126458",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16991,
                    "pubMedId": 30770351,
                    "title": "PDK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30770351"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19410,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a head and neck squamous cell carcinoma cell line harboring NOTCH1 Q1957* demonstrated apoptotic activity and reduced colony growth when treated with GSK2126458 in culture (PMID: 30770351).",
            "molecularProfile": {
                "id": 34083,
                "profileName": "NOTCH1 Q1957*"
            },
            "therapy": {
                "id": 763,
                "therapyName": "GSK2126458",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16991,
                    "pubMedId": 30770351,
                    "title": "PDK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30770351"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19411,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a head and neck squamous cell carcinoma cell line harboring NOTCH1 E1679* demonstrated apoptotic activity and reduced colony growth in culture and tumor regression in cell line xenograft models when treated with GSK2126458 (PMID: 30770351).",
            "molecularProfile": {
                "id": 34082,
                "profileName": "NOTCH1 E1679*"
            },
            "therapy": {
                "id": 763,
                "therapyName": "GSK2126458",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16991,
                    "pubMedId": 30770351,
                    "title": "PDK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30770351"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19412,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a head and neck squamous cell carcinoma cell line harboring NOTCH1 E694* demonstrated apoptotic activity and reduced colony growth when treated with GSK2126458 in culture (PMID: 30770351).",
            "molecularProfile": {
                "id": 34084,
                "profileName": "NOTCH1 E694*"
            },
            "therapy": {
                "id": 763,
                "therapyName": "GSK2126458",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16991,
                    "pubMedId": 30770351,
                    "title": "PDK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30770351"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19413,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a head and neck squamous cell carcinoma cell line harboring NOTCH1 C344fs demonstrated apoptotic activity and reduced colony growth when treated with GSK2126458 in culture (PMID: 30770351).",
            "molecularProfile": {
                "id": 34085,
                "profileName": "NOTCH1 C344fs"
            },
            "therapy": {
                "id": 763,
                "therapyName": "GSK2126458",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16991,
                    "pubMedId": 30770351,
                    "title": "PDK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30770351"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19414,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a head and neck squamous cell carcinoma cell line harboring NOTCH1 H2018fs demonstrated apoptotic activity and reduced colony growth when treated with GSK2126458 in culture (PMID: 30770351).",
            "molecularProfile": {
                "id": 34086,
                "profileName": "NOTCH1 H2018fs"
            },
            "therapy": {
                "id": 763,
                "therapyName": "GSK2126458",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16991,
                    "pubMedId": 30770351,
                    "title": "PDK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30770351"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19415,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a head and neck squamous cell carcinoma cell line harboring NOTCH1 V489fs demonstrated apoptotic activity and reduced colony growth when treated with GSK2126458 in culture (PMID: 30770351).",
            "molecularProfile": {
                "id": 34087,
                "profileName": "NOTCH1 V489fs"
            },
            "therapy": {
                "id": 763,
                "therapyName": "GSK2126458",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16991,
                    "pubMedId": 30770351,
                    "title": "PDK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30770351"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19416,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a head and neck squamous cell carcinoma cell line harboring NOTCH1 G192* demonstrated apoptotic activity and reduced colony growth when treated with GSK2126458 in culture (PMID: 30770351).",
            "molecularProfile": {
                "id": 34088,
                "profileName": "NOTCH1 G192*"
            },
            "therapy": {
                "id": 763,
                "therapyName": "GSK2126458",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16991,
                    "pubMedId": 30770351,
                    "title": "PDK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30770351"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19417,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, head and neck squamous cell carcinoma xenograft models harboring NOTCH1 C478F demonstrated reduced tumor size when treated with PQR309 (bimiralisib) (PMID: 30770351).",
            "molecularProfile": {
                "id": 10166,
                "profileName": "NOTCH1 C478F"
            },
            "therapy": {
                "id": 2019,
                "therapyName": "PQR309",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16991,
                    "pubMedId": 30770351,
                    "title": "PDK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30770351"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19418,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, head and neck squamous cell carcinoma cells harboring NOTCH1 C478F and overexpressing PDK1 demonstrated a decrease in apoptotic activity compared to the cells not overexpressing PDK1 when treated with GSK2126458 (PMID: 30770351).",
            "molecularProfile": {
                "id": 34089,
                "profileName": "NOTCH1 C478F PDK1 over exp"
            },
            "therapy": {
                "id": 763,
                "therapyName": "GSK2126458",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 16991,
                    "pubMedId": 30770351,
                    "title": "PDK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30770351"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19419,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, head and neck squamous cell carcinoma cells harboring NOTCH1 E1679* and overexpressing PDK1 demonstrated a decrease in apoptotic activity compared to the cells not overexpressing PDK1 when treated with GSK2126458 (PMID: 30770351).",
            "molecularProfile": {
                "id": 34090,
                "profileName": "NOTCH1 E1679* PDK1 over exp"
            },
            "therapy": {
                "id": 763,
                "therapyName": "GSK2126458",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 16991,
                    "pubMedId": 30770351,
                    "title": "PDK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30770351"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19420,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, head and neck squamous cell carcinoma cells harboring NOTCH1 Q1957* and overexpressing PDK1 demonstrated a decrease in apoptotic activity compared to the cells not overexpressing PDK1 when treated with GSK2126458 (PMID: 30770351).",
            "molecularProfile": {
                "id": 34091,
                "profileName": "NOTCH1 Q1957* PDK1 over exp"
            },
            "therapy": {
                "id": 763,
                "therapyName": "GSK2126458",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 16991,
                    "pubMedId": 30770351,
                    "title": "PDK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30770351"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19448,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Zarnestra (tipifarnib) treatment resulted in an overall response rate of 53% (8/15, 8 partial response) in patients with head and neck squamous cell carcinoma harboring HRAS missense mutations at a variant allele frequency over 35%, and stable disease in 5 patients, with a median progression-free survival of 5.4 months (AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Oct 2019, abstract PR08; NCT02383927).",
            "molecularProfile": {
                "id": 1208,
                "profileName": "HRAS mutant"
            },
            "therapy": {
                "id": 938,
                "therapyName": "Tipifarnib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17085,
                    "pubMedId": null,
                    "title": "Preliminary results from a phase 2 trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations.",
                    "url": "https://eventpilotadmin.com/web/planner.php?id=AACR19MT"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20160,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Ina Phase Ib/II trial, Lenvima (lenvatinib) and Keytruda (pembrolizumab) combination treatment demonstrated safety and efficacy, resulted in an objective response rate of 46% (10/22) in patients with metastatic head and neck squamous cell carcinoma, with a median duration of response of 8.2 months, and a median progression-free survival of 4.7 months (PMID: 31961766; NCT02501096).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4782,
                "therapyName": "Lenvatinib + Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 17720,
                    "pubMedId": 31961766,
                    "title": "Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31961766"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20615,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Clinoril (sulindac) treatment reduced tumor growth rate in patient-derived xenograft (PDX) models of head and neck squamous cell carcinoma harboring PIK3CA mutations (PMID: 30683736).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2126,
                "therapyName": "Sulindac",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 17965,
                    "pubMedId": 30683736,
                    "title": "Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30683736"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20616,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Celebra (celecoxib) treatment reduced tumor growth rate in a patient-derived xenograft (PDX) model of head and neck squamous cell carcinoma harboring PIK3CA M1043V (PMID: 30683736).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2124,
                "therapyName": "Celecoxib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 17965,
                    "pubMedId": 30683736,
                    "title": "Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30683736"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20617,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Clinoril (sulindac) treatment inhibited proliferation of COX2 overexpressing head and neck squamous cell carcinoma cells harboring PIK3CA mutations, including a cell line overxpressing PIK3CA H1047R in culture (PMID: 30683736).",
            "molecularProfile": {
                "id": 27149,
                "profileName": "COX2 over exp"
            },
            "therapy": {
                "id": 2126,
                "therapyName": "Sulindac",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17965,
                    "pubMedId": 30683736,
                    "title": "Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30683736"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT00573989",
            "title": "Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1290,
                    "therapyName": "Erlotinib + Pemetrexed",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00588770",
            "title": "Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                },
                {
                    "id": 1835,
                    "therapyName": "Cisplatin + Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 1833,
                    "therapyName": "Cisplatin + Fluorouracil",
                    "synonyms": null
                },
                {
                    "id": 1834,
                    "therapyName": "Carboplatin + Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 1832,
                    "therapyName": "Carboplatin + Fluorouracil",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00660218",
            "title": "A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 1988,
                    "therapyName": "Cetuximab + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00904345",
            "title": "Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 694,
                    "therapyName": "Cetuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00956007",
            "title": "Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 694,
                    "therapyName": "Cetuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00957853",
            "title": "Preoperative Treatment With Cetuximab and/or IMC-A12",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 694,
                    "therapyName": "Cetuximab",
                    "synonyms": null
                },
                {
                    "id": 701,
                    "therapyName": "Cixutumumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01064479",
            "title": "Docetaxel And Cisplatin With or Without Erlotinib For Metastatic Or Recurrent Squamous Cell Carcinoma Of Head And Neck",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4,
                    "therapyName": "Erlotinib",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01104922",
            "title": "Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 694,
                    "therapyName": "Cetuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01111058",
            "title": "Everolimus Versus Placebo in Head and Neck Cancer",
            "phase": "Phase II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 735,
                    "therapyName": "Everolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01116336",
            "title": "Phase I Chemoprevention Trial With Green Tea Polyphenon E and Erlotinib in Patients With Premalignant Lesions of the Head and Neck",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4,
                    "therapyName": "Erlotinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01133678",
            "title": "Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck",
            "phase": "Phase II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 1790,
                    "therapyName": "Cetuximab + Cisplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 735,
                    "therapyName": "Everolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01307267",
            "title": "A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 6111,
                    "therapyName": "Rituximab + Utomilumab",
                    "synonyms": null
                },
                {
                    "id": 5086,
                    "therapyName": "Utomilumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01316757",
            "title": "Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1921,
                    "therapyName": "Carboplatin + Cetuximab + Erlotinib + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01345669",
            "title": "LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy",
            "phase": "Phase III",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 623,
                    "therapyName": "Afatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01351103",
            "title": "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1937,
                    "therapyName": "LGK974",
                    "synonyms": null
                },
                {
                    "id": 7468,
                    "therapyName": "LGK974 + Spartalizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01412229",
            "title": "Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1957,
                    "therapyName": "Carboplatin + Cetuximab + Nab-paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01437449",
            "title": "Weekly Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1987,
                    "therapyName": "Cetuximab + Cisplatin + Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01467115",
            "title": "INDUCTION CHEMOTHERAPY FOLLOWED BY CETUXIMAB AND RADIATION THERAPY FOR HEAD AND NECK CANCER",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1642,
                    "therapyName": "Leucovorin",
                    "synonyms": null
                },
                {
                    "id": 1930,
                    "therapyName": "Cisplatin + Docetaxel + Fluorouracil",
                    "synonyms": null
                },
                {
                    "id": 1632,
                    "therapyName": "Filgrastim",
                    "synonyms": null
                },
                {
                    "id": 694,
                    "therapyName": "Cetuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01468896",
            "title": "Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 694,
                    "therapyName": "Cetuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01488318",
            "title": "Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1820,
                    "therapyName": "Cetuximab + Dasatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01577173",
            "title": "A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 694,
                    "therapyName": "Cetuximab",
                    "synonyms": null
                },
                {
                    "id": 806,
                    "therapyName": "Duligotuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01581970",
            "title": "Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head &amp; Neck Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1997,
                    "therapyName": "Cetuximab + Cyclophosphamide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01602315",
            "title": "A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1837,
                    "therapyName": "Alpelisib + Cetuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01607905",
            "title": "Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1749,
                    "therapyName": "Selinexor",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01612351",
            "title": "Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2477,
                    "therapyName": "Carboplatin + Cisplatin + Lapatinib + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 2476,
                    "therapyName": "Carboplatin + Lapatinib + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01642342",
            "title": "Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3013,
                    "therapyName": "sEphB4-HSA",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01711541",
            "title": "Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1544,
                    "therapyName": "Carboplatin + Etoposide + Veliparib",
                    "synonyms": null
                },
                {
                    "id": 1849,
                    "therapyName": "Cisplatin + Fluorouracil + Hydroxyurea",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01711658",
            "title": "TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 2475,
                    "therapyName": "Cisplatin + Lapatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01716416",
            "title": "Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1838,
                    "therapyName": "Cetuximab + Pazopanib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01737008",
            "title": "Study of Dacomitinib With Radiotherapy With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 714,
                    "therapyName": "Dacomitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01744340",
            "title": "A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 728,
                    "therapyName": "Eribulin",
                    "synonyms": null
                },
                {
                    "id": 694,
                    "therapyName": "Cetuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01783587",
            "title": "Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 623,
                    "therapyName": "Afatinib",
                    "synonyms": null
                },
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01794845",
            "title": "Phase II Trial Using Erbitux+ Taxotere With Low Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1925,
                    "therapyName": "Cetuximab + Docetaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01810913",
            "title": "Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 1925,
                    "therapyName": "Cetuximab + Docetaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01816984",
            "title": "PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 694,
                    "therapyName": "Cetuximab",
                    "synonyms": null
                },
                {
                    "id": 680,
                    "therapyName": "Buparlisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01824823",
            "title": "Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 623,
                    "therapyName": "Afatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01836029",
            "title": "Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 2000,
                    "therapyName": "Cetuximab + Fluorouracil",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01852292",
            "title": "Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1545,
                    "therapyName": "Buparlisib + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01871311",
            "title": "A Phase I Study of the BCR-ABL Tyrosine Kinase Inhibitor Nilontinib and Cetuximab in Patients With Solid Tumors That Can be Treated With Cetuximab",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1929,
                    "therapyName": "Cetuximab + Nilotinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01920061",
            "title": "A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1287,
                    "therapyName": "Dacomitinib + Gedatolisib",
                    "synonyms": null
                },
                {
                    "id": 1286,
                    "therapyName": "Cisplatin + Gedatolisib",
                    "synonyms": null
                },
                {
                    "id": 1285,
                    "therapyName": "Docetaxel + Gedatolisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01935921",
            "title": "Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1926,
                    "therapyName": "Cetuximab + Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01946789",
            "title": "A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3060,
                    "therapyName": "ALT-803",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01966445",
            "title": "Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2919,
                    "therapyName": "GSK2849330",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01979211",
            "title": "Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 694,
                    "therapyName": "Cetuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02035527",
            "title": "Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2431,
                    "therapyName": "Cisplatin + Docetaxel + Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02057107",
            "title": "Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 694,
                    "therapyName": "Cetuximab",
                    "synonyms": null
                },
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02083692",
            "title": "Pilot Study of Metformin in Head and Neck Squamous Cell Cancer and Its Effects on Stromal-epithelial Metabolic Uncoupling",
            "phase": null,
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1031,
                    "therapyName": "Metformin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02101034",
            "title": "PD 0332991 and Cetuximab in Patients With Incurable SCCHN",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1705,
                    "therapyName": "Cetuximab + Palbociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02105636",
            "title": "Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1639,
                    "therapyName": "Methotrexate",
                    "synonyms": null
                },
                {
                    "id": 694,
                    "therapyName": "Cetuximab",
                    "synonyms": null
                },
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02110082",
            "title": "Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2066,
                    "therapyName": "Cetuximab + Urelumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02124707",
            "title": "Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1989,
                    "therapyName": "Carboplatin + Cetuximab + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02124850",
            "title": "A Phase Ib Study of Neoadjuvant Immune Biomarker Modulation With ERBITUX&#174; (Cetuximab) and VTX-2337",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 694,
                    "therapyName": "Cetuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02128906",
            "title": "Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1925,
                    "therapyName": "Cetuximab + Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02174172",
            "title": "A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 6252,
                    "therapyName": "Atezolizumab + Bevacizumab + Peg-interferon alfa-2a",
                    "synonyms": null
                },
                {
                    "id": 6253,
                    "therapyName": "Atezolizumab + Interferon alpha-2b",
                    "synonyms": null
                },
                {
                    "id": 6250,
                    "therapyName": "Atezolizumab + Peg-interferon alfa-2a",
                    "synonyms": null
                },
                {
                    "id": 6249,
                    "therapyName": "Atezolizumab + Ipilimumab",
                    "synonyms": null
                },
                {
                    "id": 1975,
                    "therapyName": "Atezolizumab + Obinutuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02178072",
            "title": "Window Trial 5-aza in HNSCC, T-tare",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 651,
                    "therapyName": "Azacitidine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02178722",
            "title": "A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037/ ECHO-202)",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4088,
                    "therapyName": "Epacadostat + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02196168",
            "title": "Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 822,
                    "therapyName": "Adavosertib",
                    "synonyms": null
                },
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02205398",
            "title": "Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1618,
                    "therapyName": "Capmatinib + Cetuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02207530",
            "title": "Phase II Study of MEDI4736 Monotherapy in the Treatment of Patients With Recurrent or Metastatic SCCHN.",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1356,
                    "therapyName": "Durvalumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02241369",
            "title": "Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 5846,
                    "therapyName": "INO-3106 + INO-9012",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02252042",
            "title": "Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1639,
                    "therapyName": "Methotrexate",
                    "synonyms": null
                },
                {
                    "id": 694,
                    "therapyName": "Cetuximab",
                    "synonyms": null
                },
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02255097",
            "title": "Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02262741",
            "title": "A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 With Tremelimumab or Tremelimumab Alone in Head and Neck Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1652,
                    "therapyName": "Tremelimumab",
                    "synonyms": null
                },
                {
                    "id": 1356,
                    "therapyName": "Durvalumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02264678",
            "title": "Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2881,
                    "therapyName": "AZD6738",
                    "synonyms": null
                },
                {
                    "id": 4737,
                    "therapyName": "AZD6738 + Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 4738,
                    "therapyName": "AZD6738 + Durvalumab",
                    "synonyms": null
                },
                {
                    "id": 4739,
                    "therapyName": "AZD6738 + Olaparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02270814",
            "title": "Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1957,
                    "therapyName": "Carboplatin + Cetuximab + Nab-paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1956,
                    "therapyName": "Cetuximab + Cisplatin + Nab-paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02277184",
            "title": "Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1955,
                    "therapyName": "Cisplatin + Ficlatuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02277197",
            "title": "Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1959,
                    "therapyName": "Cetuximab + Ficlatuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02282371",
            "title": "Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC)",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1837,
                    "therapyName": "Alpelisib + Cetuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02289209",
            "title": "Reirradiation With MK-3475 in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02291055",
            "title": "Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head &amp; Neck Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1356,
                    "therapyName": "Durvalumab",
                    "synonyms": null
                },
                {
                    "id": 3090,
                    "therapyName": "ADXS11-001",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02296684",
            "title": "Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02315066",
            "title": "Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4333,
                    "therapyName": "PF-04518600",
                    "synonyms": null
                },
                {
                    "id": 4448,
                    "therapyName": "PF-04518600 + Utomilumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02318901",
            "title": "Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1909,
                    "therapyName": "Ado-trastuzumab emtansine + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1908,
                    "therapyName": "Pembrolizumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1910,
                    "therapyName": "Cetuximab + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02319044",
            "title": "Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1356,
                    "therapyName": "Durvalumab",
                    "synonyms": null
                },
                {
                    "id": 1652,
                    "therapyName": "Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02325401",
            "title": "Dose-finding Study of Metformin With Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2205,
                    "therapyName": "Cisplatin + Metformin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02327078",
            "title": "A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3059,
                    "therapyName": "Epacadostat + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02334319",
            "title": "Ganetespib Window of Opportunity Study in Head and Neck Cancers",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 745,
                    "therapyName": "Ganetespib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02335918",
            "title": "A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2526,
                    "therapyName": "Nivolumab + Varlilumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02358031",
            "title": "A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 694,
                    "therapyName": "Cetuximab",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1715,
                    "therapyName": "Fluorouracil",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02365662",
            "title": "A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2914,
                    "therapyName": "ABBV-221",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02369874",
            "title": "Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2439,
                    "therapyName": "Durvalumab + Tremelimumab",
                    "synonyms": null
                },
                {
                    "id": 1356,
                    "therapyName": "Durvalumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02375958",
            "title": "PCA062 in pCAD-positive Tumors.",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 7202,
                    "therapyName": "PCA062",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02381314",
            "title": "Safety Study of MGA271 in Combination With Ipilimumab in Refractory Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3058,
                    "therapyName": "Ipilimumab + MGA271",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02381535",
            "title": "Hsp90 Inhibitor AT13387 in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 645,
                    "therapyName": "Onalespib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02402348",
            "title": "Pilot Study of Metformin in HNSCC to Investigate the Effects of MF, Tumor Genotype and MF-genotype Interactions, on Tumor Metabolism and Anoikis",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1031,
                    "therapyName": "Metformin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02415881",
            "title": "Phase I Panitumumab IRDye800 Optical Imaging Study",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 845,
                    "therapyName": "Panitumumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02422979",
            "title": "Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2918,
                    "therapyName": "RM-1929",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02423863",
            "title": "In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2595,
                    "therapyName": "Poly ICLC",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02432963",
            "title": "Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5547,
                    "therapyName": "MVAp53 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02433626",
            "title": "Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (COTI2-101)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6962,
                    "therapyName": "COTI-2",
                    "synonyms": null
                },
                {
                    "id": 8277,
                    "therapyName": "Cisplatin + COTI-2",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02444793",
            "title": "A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 6332,
                    "therapyName": "Mogamulizumab + Utomilumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02449681",
            "title": "Study for Treatment of Patients With Recurrent or Metastatic SCCHN or SCCS",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2910,
                    "therapyName": "TH-4000",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02452424",
            "title": "A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2736,
                    "therapyName": "Pembrolizumab + Pexidartinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02454179",
            "title": "Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Head and Neck Squamous Cell Carcinoma",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1605,
                    "therapyName": "Acalabrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02473731",
            "title": "A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2054,
                    "therapyName": "CDX-3379",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02475213",
            "title": "Safety Study of MGA271 in Combination With Pembrolizumab in Refractory Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2864,
                    "therapyName": "MGA271 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02479178",
            "title": "A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck (iNSITE2)",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 3640,
                    "therapyName": "BIND-014",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02499120",
            "title": "Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 850,
                    "therapyName": "Palbociclib",
                    "synonyms": null
                },
                {
                    "id": 694,
                    "therapyName": "Cetuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02499328",
            "title": "Study to Assess Combination of MEDI4736 With Either AZD9150 or AZD5069 in Patients With Metastatic Squamous Cell Carcinoma of Head and Neck",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3098,
                    "therapyName": "AZD9150 + Durvalumab",
                    "synonyms": null
                },
                {
                    "id": 3099,
                    "therapyName": "AZD5069 + Durvalumab",
                    "synonyms": null
                },
                {
                    "id": 1356,
                    "therapyName": "Durvalumab",
                    "synonyms": null
                },
                {
                    "id": 2782,
                    "therapyName": "AZD9150",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02501096",
            "title": "Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 792,
                    "therapyName": "Lenvatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02508246",
            "title": "AZD1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 822,
                    "therapyName": "Adavosertib",
                    "synonyms": null
                },
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02526017",
            "title": "Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2840,
                    "therapyName": "Cabiralizumab",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02528357",
            "title": "GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5177,
                    "therapyName": "GSK3174998",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02537223",
            "title": "Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 691,
                    "therapyName": "Alpelisib",
                    "synonyms": null
                },
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02538510",
            "title": "Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer and Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3077,
                    "therapyName": "Pembrolizumab + Vorinostat",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02540291",
            "title": "Study of E7046 in Subjects With Selected Advanced Malignancies",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 5694,
                    "therapyName": "E7046",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02551159",
            "title": "Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care (SOC) in SCCHN",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 1356,
                    "therapyName": "Durvalumab",
                    "synonyms": null
                },
                {
                    "id": 1914,
                    "therapyName": "Carboplatin + Cetuximab + Fluorouracil",
                    "synonyms": null
                },
                {
                    "id": 1652,
                    "therapyName": "Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02554812",
            "title": "A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6045,
                    "therapyName": "Avelumab + PF-04518600",
                    "synonyms": null
                },
                {
                    "id": 8286,
                    "therapyName": "Avelumab + PD 0360324",
                    "synonyms": null
                },
                {
                    "id": 6043,
                    "therapyName": "Avelumab + Utomilumab",
                    "synonyms": null
                },
                {
                    "id": 6044,
                    "therapyName": "Avelumab + PF-04518600 + Utomilumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02555644",
            "title": "A Study of LY2606368 With Chemotherapy and Radiation in Participants With Head and Neck Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1651,
                    "therapyName": "Prexasertib",
                    "synonyms": null
                },
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 694,
                    "therapyName": "Cetuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02559492",
            "title": "INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 3096,
                    "therapyName": "Epacadostat + Itacitinib",
                    "synonyms": null
                },
                {
                    "id": 3097,
                    "therapyName": "Itacitinib + Parsaclisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02567422",
            "title": "VX-970, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced HPV-Negative Head and Neck Squamous Cell Carcinoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3109,
                    "therapyName": "Cisplatin + VX-970",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02573493",
            "title": "Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3126,
                    "therapyName": "Cisplatin + Nab-paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 3127,
                    "therapyName": "Cetuximab + Nab-paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02585973",
            "title": "Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1725,
                    "therapyName": "Adavosertib + Cisplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02586207",
            "title": "Pembrolizumab in Combination With CRT for LA-SCCHN",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3256,
                    "therapyName": "Cisplatin + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02609503",
            "title": "Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02626000",
            "title": "Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4035,
                    "therapyName": "Pembrolizumab + Talimogene laherparepvec",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02628535",
            "title": "Safety Study of MGD009 in B7-H3-expressing Tumors",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 6631,
                    "therapyName": "MGD009",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02630420",
            "title": "Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 3790,
                    "therapyName": "Cetuximab + Savolitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02636036",
            "title": "Study of Enadenotucirev and Pembrolizumab in Subjects With Metastatic or Advanced Epithelial Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3620,
                    "therapyName": "Enadenotucirev + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02641093",
            "title": "Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02643303",
            "title": "A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3385,
                    "therapyName": "Durvalumab + Poly ICLC",
                    "synonyms": null
                },
                {
                    "id": 1652,
                    "therapyName": "Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02643550",
            "title": "Study of IPH2201 (Monalizumab) and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3383,
                    "therapyName": "Cetuximab + IPH2201",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02644122",
            "title": "SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 915,
                    "therapyName": "SF1126",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02644369",
            "title": "Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors (INSPIRE)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02646748",
            "title": "Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7159,
                    "therapyName": "Itacitinib + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 8295,
                    "therapyName": "Parsaclisib + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02649530",
            "title": "An Open Label, Non-randomized Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 1937,
                    "therapyName": "LGK974",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02658214",
            "title": "Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 8330,
                    "therapyName": "Cisplatin + Durvalumab + Fluorouracil + Tremelimumab",
                    "synonyms": null
                },
                {
                    "id": 8329,
                    "therapyName": "Durvalumab + Gemcitabine + Nab-paclitaxel + Tremelimumab",
                    "synonyms": null
                },
                {
                    "id": 8328,
                    "therapyName": "Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin + Tremelimumab",
                    "synonyms": null
                },
                {
                    "id": 8327,
                    "therapyName": "Carboplatin + Durvalumab + Nab-paclitaxel + Tremelimumab",
                    "synonyms": null
                },
                {
                    "id": 8326,
                    "therapyName": "Carboplatin + Durvalumab + Etoposide + Tremelimumab",
                    "synonyms": null
                },
                {
                    "id": 8325,
                    "therapyName": "Carboplatin + Durvalumab + Paclitaxel + Tremelimumab",
                    "synonyms": null
                },
                {
                    "id": 7524,
                    "therapyName": "Carboplatin + Durvalumab + Gemcitabine + Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02665416",
            "title": "Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3468,
                    "therapyName": "RO5520985 + RO7009789",
                    "synonyms": null
                },
                {
                    "id": 8302,
                    "therapyName": "Bevacizumab + RO7009789",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02684253",
            "title": "Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02706691",
            "title": "Pan FGFR Kinase Inhibitor BGJ398 in Treating Patients With FGFR1-3 Translocated, Mutated, or Amplified Recurrent Head and Neck Cancer",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 674,
                    "therapyName": "BGJ398",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02741570",
            "title": "Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4168,
                    "therapyName": "Carboplatin + Cetuximab + Cisplatin + Fluorouracil",
                    "synonyms": null
                },
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02762513",
            "title": "Expansion Trial for Axitinib In Head And Neck Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 649,
                    "therapyName": "Axitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02764593",
            "title": "Chemotherapy +/- Nivolumab in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 4760,
                    "therapyName": "Cisplatin + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 4761,
                    "therapyName": "Cetuximab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02769520",
            "title": "Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02775812",
            "title": "Cisplatin, Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3256,
                    "therapyName": "Cisplatin + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02777385",
            "title": "Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3256,
                    "therapyName": "Cisplatin + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02812524",
            "title": "Ipilimumab for Head and Neck Cancer Patients",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02823574",
            "title": "Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02827838",
            "title": "Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1356,
                    "therapyName": "Durvalumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02834247",
            "title": "A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 4680,
                    "therapyName": "Nivolumab + TAK-659",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02880371",
            "title": "A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4608,
                    "therapyName": "ARRY-382 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02892201",
            "title": "Pembrolizumab in HNSCC With Residual Disease After Radiation",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02949700",
            "title": "Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2205,
                    "therapyName": "Cisplatin + Metformin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02952586",
            "title": "Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 5052,
                    "therapyName": "Avelumab + Cisplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02960594",
            "title": "hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 5844,
                    "therapyName": "INO-1400 + INO-9012",
                    "synonyms": null
                },
                {
                    "id": 5807,
                    "therapyName": "INO-1400",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02979977",
            "title": "Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Recurrent or Metastatic Squamous Cell Cancers of the Head and Neck",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4190,
                    "therapyName": "Afatinib + Cetuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02989064",
            "title": "MAGE-A10c796T for Urothelial Cancer, Melanoma or Head and Neck Cancers",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                
            ]
        },
        {
            "nctId": "NCT02990468",
            "title": "A Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer (BMX-HN)",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5840,
                    "therapyName": "BMX-001 + Cisplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03019003",
            "title": "A Phase IB/II Study With Azacitidine, Durvalumab, and Tremelimumab in Recurrent and/or Metastatic Head and Neck Cancer Patients",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5199,
                    "therapyName": "Azacitidine + Durvalumab + Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03022409",
            "title": "A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 837,
                    "therapyName": "Olaparib",
                    "synonyms": null
                },
                {
                    "id": 2881,
                    "therapyName": "AZD6738",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03049618",
            "title": "Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3944,
                    "therapyName": "Pembrolizumab + sEphB4-HSA",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03057613",
            "title": "A Study of the Addition of Pembrolizumab to Postoperative Radiotherapy in Resected High Risk Cutaneous Squamous Cell Cancer of the Head and Neck",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03065062",
            "title": "Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4034,
                    "therapyName": "Gedatolisib + Palbociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03071757",
            "title": "A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5446,
                    "therapyName": "ABBV-368",
                    "synonyms": null
                },
                {
                    "id": 5447,
                    "therapyName": "ABBV-368 + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03076281",
            "title": "Metformin Hydrochloride and Doxycycline in Treating Patients With Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1391,
                    "therapyName": "Doxycycline",
                    "synonyms": null
                },
                {
                    "id": 4610,
                    "therapyName": "Doxycycline + Metformin",
                    "synonyms": null
                },
                {
                    "id": 1031,
                    "therapyName": "Metformin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03076372",
            "title": "A Study Evaluating MM-310 in Patients With Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 5758,
                    "therapyName": "MM-310",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03082534",
            "title": "Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1910,
                    "therapyName": "Cetuximab + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03083873",
            "title": "Study of LN-145 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6772,
                    "therapyName": "LN-145",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03085719",
            "title": "Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03098160",
            "title": "Immunotherapy Study of Evofosfamide in Combination With Ipilimumab",
            "phase": "Phase I",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 5745,
                    "therapyName": "Evofosfamide + Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03109158",
            "title": "NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 5578,
                    "therapyName": "Cetuximab + Fluorouracil + NC-6004",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03126110",
            "title": "Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5599,
                    "therapyName": "INCAGN01876 + Ipilimumab + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 5598,
                    "therapyName": "INCAGN01876 + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 5597,
                    "therapyName": "INCAGN01876 + Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03132922",
            "title": "MAGE-A4c1032T for Multi-Tumor",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7280,
                    "therapyName": "ADP-A2M4 cells",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03138070",
            "title": "A Window of Opportunity Study to Assess the Modulation of Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) By Preoperative Treatment With BYL719",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 691,
                    "therapyName": "Alpelisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03153982",
            "title": "Ruxolitinib in Operable Head and Neck Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 907,
                    "therapyName": "Ruxolitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03162224",
            "title": "Safety and Efficacy of MEDI0457 and Durvalumab in Patients With HPV Associated Recurrent/Metastatic Head and Neck Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5791,
                    "therapyName": "Durvalumab + MEDI0457",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03162731",
            "title": "Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage IVA-B Head and Neck Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03174275",
            "title": "Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5873,
                    "therapyName": "Carboplatin + Cisplatin + Durvalumab + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 3997,
                    "therapyName": "Carboplatin + Durvalumab + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03194373",
            "title": "Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4735,
                    "therapyName": "Carboplatin + Palbociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03234712",
            "title": "A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) or Its Ligands",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6975,
                    "therapyName": "ABBV-321",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03236935",
            "title": "Phase Ib of L-NMMA and Pembrolizumab",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6097,
                    "therapyName": "L-NMMA + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03238638",
            "title": "A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 4088,
                    "therapyName": "Epacadostat + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03245489",
            "title": "Pembrolizumab in Combination With Anti-platelet Therapy for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03246685",
            "title": "Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 5174,
                    "therapyName": "Pembrolizumab + PGG beta-glucan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03247309",
            "title": "TCR-engineered T Cells in Solid Tumors With Emphasis on NSCLC and HNSCC (ACTengine) (ACTengine)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7285,
                    "therapyName": "Aldesleukin + IMA201",
                    "synonyms": null
                },
                {
                    "id": 2291,
                    "therapyName": "Cyclophosphamide + Fludarabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03247712",
            "title": "Neoadjuvant Immunoradiotherapy in Head & Neck Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03254927",
            "title": "A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2061,
                    "therapyName": "CDX-3379 + Cetuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03258554",
            "title": "Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Stage III-IVB Head and Neck Cancer Who Cannot Take Cisplatin",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 694,
                    "therapyName": "Cetuximab",
                    "synonyms": null
                },
                {
                    "id": 1356,
                    "therapyName": "Durvalumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03264066",
            "title": "A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6094,
                    "therapyName": "Atezolizumab + Cabozantinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03265080",
            "title": "Expressing Personalized Tumor Antigens Study",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7157,
                    "therapyName": "ADXS-NEO",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03283605",
            "title": "Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2439,
                    "therapyName": "Durvalumab + Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03289962",
            "title": "A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6234,
                    "therapyName": "RO7198457",
                    "synonyms": null
                },
                {
                    "id": 6235,
                    "therapyName": "Atezolizumab + RO7198457",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03301896",
            "title": "Phase I/Ib Study of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6299,
                    "therapyName": "LHC165 + Spartalizumab",
                    "synonyms": null
                },
                {
                    "id": 6298,
                    "therapyName": "LHC165",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03311334",
            "title": "A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Subjects With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6589,
                    "therapyName": "Atezolizumab + DSP-7888",
                    "synonyms": null
                },
                {
                    "id": 6588,
                    "therapyName": "DSP-7888 + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03313778",
            "title": "Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors (KEYNOTE-603)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6349,
                    "therapyName": "mRNA-4157 + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 6348,
                    "therapyName": "mRNA-4157",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03313804",
            "title": "Priming Immunotherapy in Advanced Disease With Radiation",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1201,
                    "therapyName": "Atezolizumab",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03319459",
            "title": "FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6375,
                    "therapyName": "FATE-NK100",
                    "synonyms": null
                },
                {
                    "id": 6376,
                    "therapyName": "FATE-NK100 + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 6377,
                    "therapyName": "Cetuximab + FATE-NK100",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03325465",
            "title": "Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 4088,
                    "therapyName": "Epacadostat + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03336606",
            "title": "Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3838,
                    "therapyName": "MEDI0562",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03341936",
            "title": "Adjuvant Nivolumab and Lirilumab in Patients With Relapsed, Resectable Squamous Cell Carcinoma of the Head and Neck",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2584,
                    "therapyName": "IPH2102 + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03342352",
            "title": "Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)",
            "phase": "Phase III",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 4168,
                    "therapyName": "Carboplatin + Cetuximab + Cisplatin + Fluorouracil",
                    "synonyms": null
                },
                {
                    "id": 6473,
                    "therapyName": "Carboplatin + Cisplatin + Epacadostat + Fluorouracil + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 6474,
                    "therapyName": "Carboplatin + Cisplatin + Fluorouracil + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03342911",
            "title": "Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5303,
                    "therapyName": "Carboplatin + Nivolumab + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03343613",
            "title": "A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6504,
                    "therapyName": "LY3300054 + LY3381916",
                    "synonyms": null
                },
                {
                    "id": 6503,
                    "therapyName": "LY3381916",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03349710",
            "title": "Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer",
            "phase": "Phase III",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 694,
                    "therapyName": "Cetuximab",
                    "synonyms": null
                },
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 4761,
                    "therapyName": "Cetuximab + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 4760,
                    "therapyName": "Cisplatin + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03357757",
            "title": "Avelumab With Valproic Acid in Virus-associated Cancer (LATENT)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6769,
                    "therapyName": "Avelumab + Valproic acid",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03358472",
            "title": "Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1832,
                    "therapyName": "Carboplatin + Fluorouracil",
                    "synonyms": null
                },
                {
                    "id": 4088,
                    "therapyName": "Epacadostat + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1915,
                    "therapyName": "Cetuximab + Cisplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03361228",
            "title": "A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 6492,
                    "therapyName": "Epacadostat + INCB001158",
                    "synonyms": null
                },
                {
                    "id": 6493,
                    "therapyName": "Epacadostat + INCB001158 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03370276",
            "title": "Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4761,
                    "therapyName": "Cetuximab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03381183",
            "title": "IRX-2 Regimen, Durvalumab, Tremelimumab for Incurable Head and Neck Squamous Cell Carcinoma",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6590,
                    "therapyName": "Cyclophosphamide + Durvalumab + Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03386838",
            "title": "An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck",
            "phase": "Phase III",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 3569,
                    "therapyName": "BMS-986205 + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 4168,
                    "therapyName": "Carboplatin + Cetuximab + Cisplatin + Fluorouracil",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03387111",
            "title": "Molecularly Informed Integrated Immunotherapy Combining Innate haNK Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With SCC Who Have Progressed on or After Platinum-based Chemotherapy and Anti- PD-1/ PD-L1 Therapy",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1105,
                    "therapyName": "Capecitabine",
                    "synonyms": null
                },
                {
                    "id": 619,
                    "therapyName": "Nab-paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1642,
                    "therapyName": "Leucovorin",
                    "synonyms": null
                },
                {
                    "id": 6570,
                    "therapyName": "GI-6301",
                    "synonyms": null
                },
                {
                    "id": 6569,
                    "therapyName": "GI-6207",
                    "synonyms": null
                },
                {
                    "id": 3144,
                    "therapyName": "Avelumab",
                    "synonyms": null
                },
                {
                    "id": 6568,
                    "therapyName": "ETBX-021",
                    "synonyms": null
                },
                {
                    "id": 6562,
                    "therapyName": "ETBX-051",
                    "synonyms": null
                },
                {
                    "id": 6561,
                    "therapyName": "ETBX-061",
                    "synonyms": null
                },
                {
                    "id": 1440,
                    "therapyName": "Aldoxorubicin",
                    "synonyms": null
                },
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 1148,
                    "therapyName": "Cyclophosphamide",
                    "synonyms": null
                },
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                },
                {
                    "id": 826,
                    "therapyName": "Necitumumab",
                    "synonyms": null
                },
                {
                    "id": 1018,
                    "therapyName": "GI-4000",
                    "synonyms": null
                },
                {
                    "id": 694,
                    "therapyName": "Cetuximab",
                    "synonyms": null
                },
                {
                    "id": 3060,
                    "therapyName": "ALT-803",
                    "synonyms": null
                },
                {
                    "id": 1715,
                    "therapyName": "Fluorouracil",
                    "synonyms": null
                },
                {
                    "id": 6163,
                    "therapyName": "ETBX-011",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03409458",
            "title": "A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab (PAVE-1)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6629,
                    "therapyName": "Avelumab + PT-112",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03416335",
            "title": "A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8822,
                    "therapyName": "DSP-0509",
                    "synonyms": null
                },
                {
                    "id": 8823,
                    "therapyName": "DSP-0509 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03422536",
            "title": "Ficlatuzumab With or Without Cetuximab in Treating Patients With Cetuximab-Resistant, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 740,
                    "therapyName": "Ficlatuzumab",
                    "synonyms": null
                },
                {
                    "id": 1959,
                    "therapyName": "Cetuximab + Ficlatuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03447314",
            "title": "Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 6865,
                    "therapyName": "GSK1795091 + GSK3174998",
                    "synonyms": null
                },
                {
                    "id": 5177,
                    "therapyName": "GSK3174998",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03452137",
            "title": "A Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1201,
                    "therapyName": "Atezolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03463161",
            "title": "Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior Immunotherapy (ORKA)",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 4088,
                    "therapyName": "Epacadostat + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03468218",
            "title": "Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer Who Have Failed Platinum Based Therapy",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5680,
                    "therapyName": "Cabozantinib + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03474497",
            "title": "Intralesional IL-2, Hypofractionated Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6823,
                    "therapyName": "Aldesleukin + Pembrolizumab + Radiotherapy",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03485209",
            "title": "Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6113,
                    "therapyName": "Tisotumab Vedotin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03498378",
            "title": "Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6883,
                    "therapyName": "Avelumab + Cetuximab + Palbociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03509012",
            "title": "Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5305,
                    "therapyName": "Carboplatin + Cisplatin + Durvalumab + Etoposide + Tremelimumab",
                    "synonyms": null
                },
                {
                    "id": 6905,
                    "therapyName": "Carboplatin + Cisplatin + Durvalumab + Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 6904,
                    "therapyName": "Cisplatin + Durvalumab + Etoposide",
                    "synonyms": null
                },
                {
                    "id": 6903,
                    "therapyName": "Cisplatin + Durvalumab",
                    "synonyms": null
                },
                {
                    "id": 3997,
                    "therapyName": "Carboplatin + Durvalumab + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 5306,
                    "therapyName": "Carboplatin + Cisplatin + Durvalumab + Etoposide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03517488",
            "title": "A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6973,
                    "therapyName": "XmAb20717",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03521570",
            "title": "Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03522584",
            "title": "Durvalumab, Tremelimumab and Stereotactic Body Radiation Therapy in Treating Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2439,
                    "therapyName": "Durvalumab + Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03524326",
            "title": "Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6943,
                    "therapyName": "Cetuximab + Lenvatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03529422",
            "title": "Durvalumab and Tremelimumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2439,
                    "therapyName": "Durvalumab + Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03538028",
            "title": "A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6977,
                    "therapyName": "INCAGN02385",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03544723",
            "title": "Safety and Efficacy of Ad-p53 in Head and Neck Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 7042,
                    "therapyName": "Ad5CMV-p53 gene + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03546582",
            "title": "SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma (KEYSTROKE)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03565445",
            "title": "A Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8423,
                    "therapyName": "ASP1948 + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 8422,
                    "therapyName": "ASP1948",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03565783",
            "title": "Study of REGN2810 Prior to Surgery in Patients With Advanced-Stage, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5656,
                    "therapyName": "Cemiplimab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03589339",
            "title": "NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9411,
                    "therapyName": "NBTXR3",
                    "synonyms": null
                },
                {
                    "id": 9412,
                    "therapyName": "NBTXR3 + unspecified PD-1 antibody",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03590054",
            "title": "A Phase 1b Dose Escalation/Expansion Study of Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7282,
                    "therapyName": "Abexinostat + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03596372",
            "title": "Study of BAY1834942 in Patients With Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7305,
                    "therapyName": "BAY1834942",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03618654",
            "title": "Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7287,
                    "therapyName": "Durvalumab + Metformin",
                    "synonyms": null
                },
                {
                    "id": 1356,
                    "therapyName": "Durvalumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03625323",
            "title": "Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC (TACTI-002)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8085,
                    "therapyName": "Eftilagimod alpha + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03628677",
            "title": "A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8176,
                    "therapyName": "AB154",
                    "synonyms": null
                },
                {
                    "id": 8177,
                    "therapyName": "AB154 + GLS-010",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03629756",
            "title": "A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8016,
                    "therapyName": "AB928 + GLS-010",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03633110",
            "title": "Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7337,
                    "therapyName": "GEN-009",
                    "synonyms": null
                },
                {
                    "id": 7338,
                    "therapyName": "GEN-009 + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03635164",
            "title": "Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1356,
                    "therapyName": "Durvalumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03637764",
            "title": "Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7075,
                    "therapyName": "Atezolizumab + Isatuximab",
                    "synonyms": null
                },
                {
                    "id": 6331,
                    "therapyName": "Isatuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03645928",
            "title": "Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7516,
                    "therapyName": "LN-144 + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 6772,
                    "therapyName": "LN-145",
                    "synonyms": null
                },
                {
                    "id": 7517,
                    "therapyName": "LN-145 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03646461",
            "title": "Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3198,
                    "therapyName": "Ibrutinib + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 7471,
                    "therapyName": "Cetuximab + Ibrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03650764",
            "title": "Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2896,
                    "therapyName": "Pembrolizumab + Ramucirumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03652233",
            "title": "Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 7406,
                    "therapyName": "Afatinib + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03655444",
            "title": "Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7451,
                    "therapyName": "Abemaciclib + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03666273",
            "title": "A First-in-human Study of ILDR2 (Immunoglobulin-like Domain Containing Receptor 2) Function-blocking Antibody BAY1905254",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8761,
                    "therapyName": "BAY1905254",
                    "synonyms": null
                },
                {
                    "id": 8762,
                    "therapyName": "BAY1905254 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03667482",
            "title": "Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7486,
                    "therapyName": "Cabozantinib + Cetuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03674567",
            "title": "Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7533,
                    "therapyName": "FLX475 + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 7530,
                    "therapyName": "FLX475",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03690986",
            "title": "VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 6516,
                    "therapyName": "Ipilimumab + VX15/2503",
                    "synonyms": null
                },
                {
                    "id": 6517,
                    "therapyName": "Nivolumab + VX15/2503",
                    "synonyms": null
                },
                {
                    "id": 3738,
                    "therapyName": "VX15/2503",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03691714",
            "title": "Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7551,
                    "therapyName": "Cetuximab + Durvalumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03693612",
            "title": "GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7628,
                    "therapyName": "GSK3359609 + Tremelimumab",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 694,
                    "therapyName": "Cetuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03700294",
            "title": "Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 7566,
                    "therapyName": "ADCT-601",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03708224",
            "title": "Phase II Study of Perioperative Immunotherapy in Patients With Advanced Non-Virally Associated Squamous Cell Carcinoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7438,
                    "therapyName": "Atezolizumab + Emactuzumab",
                    "synonyms": null
                },
                {
                    "id": 1201,
                    "therapyName": "Atezolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03719690",
            "title": "Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy (AIM-HN/SEQ-HN)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 938,
                    "therapyName": "Tipifarnib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03735290",
            "title": "A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer (ILIAD)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 7463,
                    "therapyName": "Intuvax + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03735628",
            "title": "An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6899,
                    "therapyName": "Copanlisib + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03740100",
            "title": "Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations (HNSCC)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2019,
                    "therapyName": "PQR309",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03752398",
            "title": "A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9200,
                    "therapyName": "XmAb23104",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03758781",
            "title": "IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7122,
                    "therapyName": "Cyclophosphamide + IRX-2 + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03769311",
            "title": "Cetuximab in Head and Neck Cancer Patients",
            "phase": "Phase II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 694,
                    "therapyName": "Cetuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03771820",
            "title": "Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 8611,
                    "therapyName": "NC-6004 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03789097",
            "title": "Vaccination With Flt3L, Radiation, and Poly-ICLC",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7696,
                    "therapyName": "CDX-301 + Pembrolizumab + Poly ICLC",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03795610",
            "title": "Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 3363,
                    "therapyName": "IPI-549",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03803774",
            "title": "Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2647,
                    "therapyName": "Birinapant",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03809624",
            "title": "Study of INBRX-105 in Patients With Solid Tumors, Hodgkin or Non-Hodgkin Lymphoma (PDL1x41BB)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8934,
                    "therapyName": "INBRX-105",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03811652",
            "title": "A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 5762,
                    "therapyName": "MEDI7247",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03823131",
            "title": "Tavokinogene Telseplasmid With Electroporation, Pembrolizumab, and Epacadostat in Treating Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7798,
                    "therapyName": "Epacadostat + Pembrolizumab + Tavokinogene telseplasmid",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03829501",
            "title": "Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7826,
                    "therapyName": "Atezolizumab + KY1044",
                    "synonyms": null
                },
                {
                    "id": 7825,
                    "therapyName": "KY1044",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03849469",
            "title": "A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7902,
                    "therapyName": "Pembrolizumab + XmAb22841",
                    "synonyms": null
                },
                {
                    "id": 7901,
                    "therapyName": "XmAb22841",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03854032",
            "title": "Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 3569,
                    "therapyName": "BMS-986205 + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03871348",
            "title": "A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9295,
                    "therapyName": "SAR441000",
                    "synonyms": null
                },
                {
                    "id": 9296,
                    "therapyName": "Cemiplimab + SAR441000",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03878979",
            "title": "Preoperative Immune Checkpoint Inhibitor for Patients With Recurrent or Metastatic SCCHN Undergoing Surgical Salvage",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03893955",
            "title": "A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 and ABBV-368 With and Without ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8118,
                    "therapyName": "ABBV-368 + ABBV-927",
                    "synonyms": null
                },
                {
                    "id": 8119,
                    "therapyName": "ABBV-181 + ABBV-368 + ABBV-927",
                    "synonyms": null
                },
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03894618",
            "title": "SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8683,
                    "therapyName": "SL-279252",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03916627",
            "title": "Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5656,
                    "therapyName": "Cemiplimab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03936959",
            "title": "A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 9537,
                    "therapyName": "LY3434172",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03937141",
            "title": "Efficacy and Safety Trial of ADU-S100 and Anti-PD1 in Head and Neck Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6218,
                    "therapyName": "MIW815",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03938337",
            "title": "Clinical Trial of Abemaciclib in Combination With Pembrolizumab in Patients With Metastatic or Recurrent Head and Neck Cancer",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 4242,
                    "therapyName": "Abemaciclib + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03944915",
            "title": "De-Escalation Therapy for Human Papillomavirus Negative Disease (DEPEND)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5303,
                    "therapyName": "Carboplatin + Nivolumab + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 8378,
                    "therapyName": "Cisplatin + Filgrastim + Fluorouracil + Hydroxyurea + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03964727",
            "title": "A Study of Sacituzumab Govitecan in Metastatic Solid Tumors (Tropics-03)",
            "phase": "Phase II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 3227,
                    "therapyName": "Sacituzumab govitecan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03973333",
            "title": "Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8448,
                    "therapyName": "Atezolizumab + IMC-C103C",
                    "synonyms": null
                },
                {
                    "id": 8447,
                    "therapyName": "IMC-C103C",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03977467",
            "title": "Atezolizumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5983,
                    "therapyName": "Atezolizumab + Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 7491,
                    "therapyName": "Atezolizumab + Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 1201,
                    "therapyName": "Atezolizumab",
                    "synonyms": null
                },
                {
                    "id": 8440,
                    "therapyName": "Atezolizumab + Bevacizumab + Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 8439,
                    "therapyName": "Atezolizumab + Bevacizumab + Cisplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03991741",
            "title": "Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 1167,
                    "therapyName": "Aldesleukin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03997968",
            "title": "A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8486,
                    "therapyName": "CYT01B",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04000529",
            "title": "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8507,
                    "therapyName": "Spartalizumab + TNO155",
                    "synonyms": null
                },
                {
                    "id": 8522,
                    "therapyName": "Ribociclib + TNO155",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04007744",
            "title": "Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8531,
                    "therapyName": "Pembrolizumab + Sonidegib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04032704",
            "title": "A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3615,
                    "therapyName": "SGN-LIV1A",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04034225",
            "title": "Addition of SNS-301 to Ongoing Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8624,
                    "therapyName": "PAN-301-1 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04052204",
            "title": "Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8711,
                    "therapyName": "Avelumab + NKTR-214",
                    "synonyms": null
                },
                {
                    "id": 8712,
                    "therapyName": "Avelumab + NKTR-214 + Talazoparib",
                    "synonyms": null
                },
                {
                    "id": 8713,
                    "therapyName": "Avelumab + Enzalutamide + NKTR-214",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04058145",
            "title": "AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 8679,
                    "therapyName": "Pembrolizumab + Plerixafor",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04069026",
            "title": "A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9716,
                    "therapyName": "BAY2416964",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04080804",
            "title": "Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 4197,
                    "therapyName": "Nivolumab + Relatlimab",
                    "synonyms": null
                },
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04091867",
            "title": "sEphB4-HSA With Cetuximab and RT in Patients With High Risk, LAHNSCC and Heavy Smoking Histories",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9204,
                    "therapyName": "Cetuximab + sEphB4-HSA",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04096638",
            "title": "Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8759,
                    "therapyName": "Nivolumab + SB 11285",
                    "synonyms": null
                },
                {
                    "id": 8758,
                    "therapyName": "SB 11285",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04114136",
            "title": "Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 5302,
                    "therapyName": "Metformin + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 6581,
                    "therapyName": "Metformin + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 8813,
                    "therapyName": "Pembrolizumab + Rosiglitazone",
                    "synonyms": null
                },
                {
                    "id": 8812,
                    "therapyName": "Nivolumab + Rosiglitazone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04122625",
            "title": "Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143 (SMARTPLUS-106)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9181,
                    "therapyName": "Debio 1143 + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04128696",
            "title": "Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (INDUCE-3)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 4410,
                    "therapyName": "GSK3359609 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04135352",
            "title": "A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9573,
                    "therapyName": "Pembrolizumab + V938",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04144517",
            "title": "A Study of ALKS 4230 With Pembrolizumab in Head and Neck Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8004,
                    "therapyName": "ALKS 4230 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04145622",
            "title": "Study of DS-7300a in Participants With Advanced Solid Malignant Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9154,
                    "therapyName": "DS-7300a",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04150900",
            "title": "1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6919,
                    "therapyName": "Bavituximab + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04152018",
            "title": "Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8931,
                    "therapyName": "PF-06801591 + PF-06940434",
                    "synonyms": null
                },
                {
                    "id": 8930,
                    "therapyName": "PF-06940434",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04188951",
            "title": "HFHS-1801-A Pilot Study of Immunotherapy as Consolidation Therapy for Patients With Recurrent Head and Neck Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04193293",
            "title": "A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9423,
                    "therapyName": "Duvelisib + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04196283",
            "title": "A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9067,
                    "therapyName": "ABBV-368 + IMO-2125",
                    "synonyms": null
                },
                {
                    "id": 9068,
                    "therapyName": "ABBV-368 + IMO-2125 + Nab-paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 9069,
                    "therapyName": "ABBV-181 + ABBV-368 + IMO-2125 + Nab-paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04198766",
            "title": "Study of INBRX-106 in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9075,
                    "therapyName": "INBRX-106",
                    "synonyms": null
                },
                {
                    "id": 9076,
                    "therapyName": "INBRX-106 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04220775",
            "title": "M7824 Plus Re-irradiation With Stereotactic Body Radiation Therapy for the Curative Intent Treatment of Recurrent Head and Neck Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 5860,
                    "therapyName": "M7824",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04247282",
            "title": "Anti-PD-L1/TGF- <= Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for p16-Negative Resectable Head and Neck Squamous Cell Carcinoma",
            "phase": "Phase Ib/II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 5860,
                    "therapyName": "M7824",
                    "synonyms": null
                },
                {
                    "id": 9290,
                    "therapyName": "ETBX-011 + ETBX-051 + ETBX-061 + M7824",
                    "synonyms": "M7824 + TriAd vaccine"
                },
                {
                    "id": 9291,
                    "therapyName": "ALT-803 + ETBX-011 + ETBX-051 + ETBX-061 + M7824",
                    "synonyms": "ALT-803 + M7824 + TriAd vaccine"
                }
            ]
        },
        {
            "nctId": "NCT04260802",
            "title": "A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers",
            "phase": "Phase Ib/II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9335,
                    "therapyName": "OC-001 + unspecified PD-L1 antibody",
                    "synonyms": null
                },
                {
                    "id": 9334,
                    "therapyName": "OC-001 + unspecified PD-1 antibody",
                    "synonyms": null
                },
                {
                    "id": 9333,
                    "therapyName": "OC-001",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04262388",
            "title": "A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation (DOME)",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 7618,
                    "therapyName": "Durvalumab + Oleclumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04266730",
            "title": "Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab (PANDA-VAC)",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9476,
                    "therapyName": "PANDA-VAC + Pembrolizumab + Poly ICLC",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04290546",
            "title": "CIML NK Cell in Head & Neck Cancer",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9454,
                    "therapyName": "ALT-803 + CIML-NK cells + Ipilimumab",
                    "synonyms": null
                },
                {
                    "id": 9455,
                    "therapyName": "ALT-803 + CIML-NK cells",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04294576",
            "title": "Safety Study of BJ-001, and IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors (FIH)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9460,
                    "therapyName": "BJ-001 + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 9459,
                    "therapyName": "BJ-001",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04313504",
            "title": "Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 6321,
                    "therapyName": "Niraparib + TSR-042",
                    "synonyms": null
                }
            ]
        }
    ]
}